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Background: There is good evidence of vaccine effectiveness in healthy individuals but less robust
evidence for vaccine effectiveness in the populations targeted for influenza vaccination. The live attenuated
influenza vaccine (LAIV) has recently been recommended for children in the UK. The trivalent influenza
vaccine (TIV) is recommended for all people aged ≥ 65 years and for those aged < 65 years who are at an
increased risk of complications from influenza infection (e.g. people with asthma).
Objective: To examine the vaccine effectiveness of LAIV and TIV.
Design: Cohort study and test-negative designs to estimate vaccine effectiveness. A self-case series study
to ascertain adverse events associated with vaccination.
Setting: A national linkage of patient-level general practice (GP) data from 230 Scottish GPs to the
Scottish Immunisation & Recall Service, Health Protection Scotland virology database, admissions to
Scottish hospitals and the Scottish death register.
Participants: A total of 1,250,000 people.
Interventions: LAIV for 2- to 11-year-olds and TIV for older people (aged ≥ 65 years) and those aged
< 65 years who are at risk of diseases, from 2010/11 to 2015/16.
Main outcome measures: The main outcome measures include vaccine effectiveness against
laboratory-confirmed influenza using real-time reverse-transcription polymerase chain reaction (RT-PCR),
influenza-related morbidity and mortality, and adverse events associated with vaccination.
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Results: Two-fifths (40%) of preschool-aged children and three-fifths (60%) of primary school-aged
children registered in study practices were vaccinated. Uptake varied among groups [e.g. most affluent
vs. most deprived in 2- to 4-year-olds, odds ratio 1.76, 95% confidence interval (CI) 1.70 to 1.82].
LAIV-adjusted vaccine effectiveness among children (aged 2–11 years) for preventing RT-PCR laboratory-
confirmed influenza was 21% (95% CI –19% to 47%) in 2014/15 and 58% (95% CI 39% to 71%) in
2015/16. No significant adverse events were associated with LAIV. Among at-risk 18- to 64-year-olds,
significant trivalent influenza vaccine effectiveness was found for four of the six seasons, with the highest
vaccine effectiveness in 2010/11 (53%, 95% CI 21% to 72%). The seasons with non-significant vaccine
effectiveness had low levels of circulating influenza virus (2011/12, 5%; 2013/14, 9%). Among those
people aged ≥ 65 years, TIV effectiveness was positive in all six seasons, but in only one of the six seasons
(2013/14) was significance achieved (57%, 95% CI 20% to 76%).
Conclusions: The study found that LAIV was safe and effective in decreasing RT-PCR-confirmed influenza
in children. TIV was safe and significantly effective in most seasons for 18- to 64-year-olds, with positive
vaccine effectiveness in most seasons for those people aged ≥ 65 years (although this was significant in
only one season).
Future work: The UK Joint Committee on Vaccination and Immunisation has recommended the use of
adjuvanted injectable vaccine for those people aged ≥ 65 years from season 2018/19 onwards. A future
study will be required to evaluate this vaccine.
Trial registration: Current Controlled Trials ISRCTN88072400.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 24, No. 67.
See the NIHR Journals Library website for further project information.
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In Scotland, a new type of influenza vaccine (live attenuated influenza vaccine), administered via the nose,was introduced in 2014/15 for all children aged between 2 and 11 years. It can be difficult to evaluate any
changes in health as a result of new immunisation programmes, given that randomised controlled trials
of vaccines are impractical and can also be seen as unethical. These changes are therefore typically not
evaluated, making it difficult to inform future policy in this field. Observational studies can be used to assess
the effects of health-care interventions without influencing the care that is provided or affecting the people
who receive it. An evaluation (effectiveness and safety) of this change in the immunisation programme was
conducted. The vaccine programme, an inactivated vaccine administered as an injection, for other groups for
whom the evidence available is limited was also evaluated [i.e. for people aged ≥ 65 years and people aged
< 65 years who have a medical condition (e.g. asthma) that puts them at risk of severe illness from influenza].
The findings support the view that the intranasal vaccine is effective and safe in preventing influenza in
children. The injectable vaccine in people aged < 65 years who are more at risk of complications from flu was
safe and effective. Lower effectiveness was found in people aged ≥ 65 years. Both the injectable vaccine and
the intranasal vaccine have high levels of uptake in the population offered vaccination. When considering
these results, the important limitation of bias in observational study designs should be noted [for instance,
residual confounding, whereby it is not possible to measure a characteristic of those people receiving the
vaccine (e.g. being healthier)], and this is accounted for in this analysis.
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Globally, there are 90 million new cases of influenza and 1 million cases of influenza-associated severe
acute lower respiratory infection per annum among children. National influenza vaccination programmes,
delivered by primary care in the community, are important to reduce influenza-related illness, and
hence the considerable investment in this approach. Previously, these programmes targeted older people
(i.e. those aged ≥ 65 years) and people with chronic disease (e.g. asthma) who are susceptible to serious
illness from influenza. Children are also thought to be important in the transmission of influenza to the
populations at risk of serious complications from influenza, and diminished circulation of the virus has
been predicted to improve herd immunity. Using evidence generated from epidemiological modelling, and
following advice from the UK Joint Committee for Vaccination and Immunisation, from September 2013
the seasonal influenza vaccination programme was extended. In addition to the seasonal trivalent influenza
vaccine (TIV), the live attenuated influenza vaccine (LAIV) is offered to all children aged 2–11 years (except
children clinically severely immunocompromised owing to conditions or immunosuppressive therapy or oral
steroids and children with severe asthma), by primary care clinicians in general practice (GP) and in schools
in Scotland.
Objectives
Building on prior work, approaches used were further refined as part of three National Institute for Health
Research Health Technology Assessment and Health Services and Delivery Research projects [Simpson CR,
Ritchie LD, Robertson C, Sheikh A, McMenamin J. Vaccine effectiveness in pandemic influenza – primary care
reporting (VIPER): an observational study to assess the effectiveness of the pandemic influenza A (H1N1)v
vaccine. Health Technol Assess 2010;14(34); Simpson CR, Lone N, Kavanagh K, Ritchie LD, Robertson C,
Sheikh A, et al. Trivalent inactivated seasonal influenza vaccine effectiveness for the prevention of laboratory
confirmed influenza in a Scottish population 2000–2009. Euro Surveill 2015;20:ii–21043; and Simpson CR,
Lone N, McMenamin J, Gunson R, Robertson C, Ritchie LD, Sheikh A. Early estimation of pandemic influenza
Antiviral and Vaccine Effectiveness (EAVE): use of a unique community and laboratory national data-linked
cohort study. Health Technol Assess 2015;19(79)]. The study determined seasonal influenza vaccine uptake
and effectiveness in the Scottish population. This involved the interrogation of data from 230 GPs (a sample
of 25% of Scotland’s practices) linked to the Health Protection Scotland virology database (Electronic
Communication of Surveillance in Scotland), the Information Services Division hospital and mortality records
(General Register Office for Scotland Death Certification and Scottish Morbidity Record 01) and the Child
Health Services Programme/Scottish Immunisation & Recall Service.
The primary objective was to evaluate:
l early estimates of the uptake and effectiveness of LAIV administered to children (from 2013).
The secondary objectives were to evaluate the:
l vaccine effectiveness of seasonal TIV among older people (aged ≥ 65 years)
l vaccine effectiveness of seasonal TIV among those people with at-risk diseases (e.g. asthma) and aged
< 65 years
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l validity of using laboratory-confirmed influenza tests from non-Sentinel primary care and secondary care
compared with Sentinel primary care practices
l validity of using laboratory-confirmed respiratory syncytial virus as a negative-control outcome
l adverse events associated with vaccination.
Methods
The setting for this project was 230 participating GPs based throughout Scotland.
Data on vaccination and other patient characteristics from GPs were linked using NHS Scotland’s unique
patient identifier, the Community Health Index number, to the Scottish Morbidity Record catalogue (inpatient
hospitalisations) and mortality within Scotland and virological real-time reverse-transcription polymerase chain
reaction (RT-PCR) data. Vaccine uptake was derived from the electronic GP record and vaccine effectiveness
was calculated using information from linked virological swab data, using a logistic regression model adjusted
for the effects of sex, age and socioeconomic status. In addition, the cohort method was used to estimate the
proportion of influenza-like illness (ILI), acute respiratory disease and other non-specific clinical outcomes, such
as hospitalisation or death from influenza, between vaccinated and unvaccinated cases.
Results
Two-fifths (40%) of preschool-aged children and three-fifths (60%) of primary school-aged children
registered in the study’s practices were vaccinated. Uptake varied among groups [e.g. most affluent vs. most
deprived in 2- to 4-year-olds, odds ratio 1.76, 95% confidence interval (CI) 1.70 to 1.82]. LAIV-adjusted
vaccine effectiveness among children (aged 2–11 years) for preventing RT-PCR laboratory-confirmed
influenza was 21% (95% CI –19% to 47%) in 2014/15 and 58% (95% CI 39% to 71%) in 2015/16. No
significant adverse events were associated with LAIV. Among at-risk 18- to 64-year-olds, significant TIV
effectiveness was found for four of the six seasons with the highest vaccine effectiveness in 2010/11 (53%,
95% CI 21% to 72%). The seasons with non-significant vaccine effectiveness had low levels of circulating
influenza virus (2011/12, 5%; 2013/14, 9%). For people aged ≥ 65 years, TIV effectiveness was positive
in all six seasons, but in only one of the six seasons (2013/14) was significance achieved (57%, 95% CI
20% to 76%). An analysis of age groups found significant vaccine effectiveness for people aged 65–74
years with asthma (53%, 95% CI 13% to 74%) and chronic kidney disease (60%, 95% CI 17% to 81%).
Furthermore, significant vaccine effectiveness was found in those aged 75–84 years with chronic respiratory
disease against influenza A(H3N2) (52%, 95% CI 11% to 74%) and in those with asthma against influenza
B (86%, 95% CI 32% to 97%). Among the oldest age group (i.e. people aged ≥ 85 years), significant
vaccine effectiveness was found for those with chronic respiratory disease (20%, 95% CI 2% to 34%),
chronic heart disease (27%, 95% CI 3% to 45%), asthma (54%, 95% CI 43% to 62%), diabetes mellitus
(34%, 95% CI 9% to 51%) and impaired immune function (42%, 95% CI 3% to 65%). TIV in adults was
also found to be safe.
In the cohort analysis for people aged ≥ 65 years, adjusted vaccine effectiveness for reducing primary care
consultations for ILIs was not significant in 2012/13 (vaccine effectiveness –64%, 95% CI –72% to –56%)
and in 2013/14 (–28%, 95% CI –34% to –23%). However, statistically significant protective vaccine
effectiveness was observed in hospitalisation due to influenza and pneumonia, ranging from 17% (95% CI
16% to 19%) in 2010/11 to 28% (95% CI 26% to 29%) in 2013/14. Vaccine effectiveness for death
attributable to influenza and pneumonia was statistically significant and ranged from 32% (95% CI 31% to
33%) in 2010/11 to 40% (95% CI 39% to 41%) in 2015/16.
SCIENTIFIC SUMMARY
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Conclusions
Few countries’ health systems allow for the integrated and accessible data recording that made this study
possible and made it feasible to centrally collate almost all hospitalisations and deaths attributed to
influenza, allowing for completeness of reporting. Using these data, LAIV was found to be safe and
effective in decreasing RT-PCR-confirmed influenza in children. TIV was safe and significantly effective
(in most seasons) for 18- to 64-year-olds, with positive vaccine effectiveness in most seasons for those
aged ≥ 65 years, although this was significant in only one season. Higher vaccine effectiveness was found
among younger adults with asthma. This should strengthen the evidence base for health-care practitioners
involved in distributing LAIV. TIV immunisation for at-risk adults aged < 65 years in primary health-care
settings is effective. The finding of limited vaccine effectiveness in people aged ≥ 65 years supports the
recent UK Joint Committee on Vaccination and Immunisation recommendation to introduce adjuvanted
vaccine for those in this age group from the 2018/19 season.
Recommendations for research
The monitoring of the LAIV programme with enhanced Sentinel swabbing of preschool- and primary
school-aged children should continue. Replication of vaccine effectiveness and safety in LAIV and TIV in
other countries that have these influenza vaccine programmes is now required to confirm the results of
this study. The Joint Committee on Vaccination and Immunisation has recommended the use of adjuvanted
injectable vaccine for those aged ≥ 65 years from season 2018/19 onwards. A future study will be required
to evaluate this vaccine.
Trial registration
This trial is registered as ISRCTN88072400.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Description of the health problem
Globally, it is estimated that seasonal influenza is responsible for 5 million cases of severe illness and
500,000 deaths per year, with, for example, an estimated cost to the USA of US$87B per annum.1–3 There
are also 90 million new cases of influenza and 1 million cases of influenza-associated severe acute lower
respiratory infection among children.4 National influenza vaccination programmes, delivered by primary
care in the community, are important to reduce influenza-related illness, and hence the considerable
investment in this approach. Previously, these programmes targeted older people (i.e. those aged ≥ 65 years)
and people with chronic disease (e.g. asthma) who are susceptible to serious illness from influenza.
Children are also thought to be important in the transmission of influenza to the populations at risk of
serious complications from influenza, and diminished circulation of the virus has been predicted to improve
herd immunity.5 Using evidence generated from epidemiological modelling,6 and following advice from
the Joint Committee on Vaccination and Immunisation, from September 2013 the seasonal influenza
vaccination programme has been extended.7 In addition to the seasonal trivalent influenza vaccine (TIV),
the live attenuated influenza vaccine (LAIV) is offered to all children aged 2–11 years (except children
clinically severely immunocompromised owing to conditions or immunosupressive therapy or oral steroids,
and children with severe asthma) by primary care clinicians in general practice (GP) and in schools
in Scotland.
Existing evidence
The evidence from clinical trials of the benefits of LAIV are largely confined to healthy children aged < 7 years
(mostly for children aged < 3 years).8,9 Efforts to estimate seasonal TIV effectiveness have been largely
confined to younger healthier adults (e.g. with no randomised controlled trials showing efficacy of TIV in
adults aged ≥ 65 years).9,10 Recent observational studies have attempted to estimate the vaccine effectiveness
in preventing influenza-related illness in GP patients.3,11 Further studies have examined vaccine effectiveness
with hospitalisation or death; however, these studies have suffered from bias when using non-specific
outcomes,8 or have been underpowered when using more specific end points (e.g. laboratory-confirmed
influenza), in particular for subgroups being targeted for vaccination (e.g. older people aged ≥ 65 years,
people with at-risk disease such as asthma and pregnant women).12 Cohort studies (with nested case–control
studies) or data linkage-derived estimates of vaccine effectiveness have been undertaken, with measures taken
to overcome many of the confounding issues that otherwise have limited estimations of effectiveness.13–15
There is also a need to add to the growing body of evidence with regard to the safety of these vaccines.16
Given the ongoing controversy regarding vaccine effectiveness and, in particular, in relation to at-risk
groups (e.g. those with asthma),7 there is further need for information to help evaluate new seasonal
vaccine strategies.
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Chapter 2 Research questions
This research aimed to examine the vaccine effectiveness and safety of the seasonal influenza vaccines,including LAIV and TIV. The research team had access to a unique set of linked databases within a
trusted research environment (TRE), which contained individual patient-level data relating to primary
health care, acute hospital care data, school immunisation data, virological real-time reverse-transcription
polymerase chain reaction (RT-PCR) laboratory tests and mortality.3
In contrast to previous observational studies, these rich data sources provide information on a large number
of potential confounders and highly specific laboratory outcome measures in a study cohort sampled from
the general population. This assessment of the vaccine effectiveness and the public health impact of a
new seasonal influenza vaccination programme seeks to clarify whether or not such a programme leads to
societal benefits, therefore advancing the international evidence base.
The research questions were:
l What was the uptake and vaccine effectiveness of LAIV administered to children (introduced to the
national vaccination programme in 2013)?
l What was the uptake and vaccine effectiveness of TIV administered to at-risk groups (e.g. those people
aged ≥ 65 years and people aged < 65 years with asthma)?
l Are laboratory-confirmed influenza tests from non-Sentinel primary care and secondary care valid
(vs. Sentinel primary care practices)?
l What was the validity of using laboratory-confirmed respiratory syncytial virus as a negative-control
outcome?
l What adverse events are associated with vaccination?
DOI: 10.3310/hta24670 HEALTH TECHNOLOGY ASSESSMENT 2020 VOL. 24 NO. 67
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Simpson et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science




Study design and population
Vaccine uptake is reported from a cross-sectional survey of all six influenza seasons. The test-negative
design (TND) was used to measure vaccine effectiveness for the RT-PCR outcomes and a cohort study
design was used for non-specific clinical outcomes (e.g. hospitalisation or death from influenza
or pneumonia).17
All practices in Scotland (n = 998) were invited to participate and 230 (self-selected) practices were
recruited These represented 29 (65.9%) of 44 of the Community Health Partnership (CHP) areas in
Scotland. Data were extracted on 1.25 million patients in Scotland into our study. Each patient contributed
person-time to each influenza season while alive and fully registered with a participating GP (i.e. a person
was included in the study if they were on a participating practice’s list of patients, including those who
may have died or deregistered during the study period).
Three basic data sets for analysis were created:
1. all patients with a RT-PCR test
2. patients by age group (e.g. 2–4, 5–11, 12–17, 18–64 and ≥ 65 years)
3. patients at risk of serious influenza-like illnesses (ILIs) (e.g. asthma).
Databases
Data fields extracted from the following databases (Figure 1) were linked deterministically using the
Community Health Index number; a unique identifier used by the NHS for the Scottish population.3 The
database linkage and analysis was carried out within the NHS National Services Scotland (NSS) TRE by
the electronic Data Research and Innovation Service (eDRIS).
General practice
Almost all individuals resident in Scotland are registered with a GP, which provides health-care services free
of charge. Virtually all specialist hospital care services are also free of charge, usually obtained through
referral from primary care or, in emergency situations, through patients attending an accident and
emergency department. Primary care-based physicians co-ordinate the influenza vaccination programme
for their patients and provide much of the care of patients discharged back into the community by
secondary and tertiary care services. Completeness of capture of contacts and accuracy of clinical event
coding (using Read codes) has been found to be > 91% among practices in Scotland.18,19 The electronic
recording of long-term prescribing information by primary care has also been found to be both accurate
and complete.20
Child Health Services Programme/Scottish Immunisation & Recall System
The Child Health Services Programme/Scottish Immunisation & Recall System database has a record of all
children (used nationally from 2002) with scheduled vaccinations. Data on vaccination administration for all
children in Scotland are also recorded here.21 These data were used to determine influenza vaccinations
that have been administered in schools rather than in primary care.
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Electronic Communication of Surveillance in Scotland
Data on > 60,000 RT-PCR tests (including an additional 1500 tests per season funded to target 2- and
3-year-olds), collated into the Electronic Communication of Surveillance in Scotland (ECOSS) database,
were used for the identification of severe disease, outbreaks and long-term trends in the incidence of
laboratory-reported infections.22
Scottish Morbidity Record
The Information Services Division (ISD) NSS maintains a database of all acute hospital discharges and deaths
in Scotland, known as the Scottish Morbidity Record 01 (SMR01). All inpatient and day-case episodes of
care for acute hospitals since 1981 have been recorded in the database. The database is subject to regular
validation checks and the most recent quality assurance report indicated good levels of accuracy (i.e. > 90%)
for the fields used in this study.23 Diagnostic information is recorded using the International Classification of
Diseases, Tenth Edition (ICD-10). There are up to six fields that can be used to record diagnoses, with one
field allocated as the main reason for admission. SMR01 is linked routinely by the ISD to the Scottish death
register using patient characteristics in a probabilistic matching algorithm, with a high degree of accuracy.24
Details from death certificates issued for all deaths in Scotland are recorded in the death register, maintained
by the National Records of Scotland.25 Cause of death has been routinely coded, using ICD-10, since 2000.3
Study period
Data from 1 September 2010 to 31 August 2016 were used. These allowed an analysis of six influenza
seasons (from 2010/11 to 2015/16). Each patient contributed person-time to each influenza season while
alive and registered with a participating GP. For the non-pandemic seasons, each year (i.e. 1 September
to 31 August) was divided in to four periods (Figure 2). The influenza season was defined for each year
using national influenza surveillance data.26 The other periods include a pre-influenza season (starting on
1 September), a post-influenza period (which ends on 31 May each year) and a ‘non-influenza’ period
(from 1 June to 31 August) (see Figure 2). Because there was a phased roll-out arrangement for influenza
Invitations and consent to 998 GPs (including sentinel PIPER and












Processed database to National Safe Haven for data linkage and
statistical analysis






FIGURE 1 Flow diagram for the Seasonal Influenza Vaccination Effectiveness II project. ECOSS, Electronic
Communication of Surveillance in Scotland; PIPER, Pandemic Influenza Primary Care Reporting; SMR01, Scottish
Morbidity Record 01.
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vaccination among children, children aged 2–3 years and primary school-aged children (for which pilots
were taking place) in season 2013/14, and all preschool children aged 2–4 years and all primary school-
aged children (i.e. all children aged 2–11 years) in seasons 2014/15 and 2015/16 were analysed.
Baseline characteristics for each patient was determined on 1 September each year. The earliest date of
influenza vaccination varied for each influenza season, but always took place after 1 September.
Exposure definition
For people in at-risk groups, influenza vaccinations (TIV and LAIV for preschool children aged ≥ 2 years) are
free and administered by general practitioners (Table 1).28 Data on influenza vaccination carried out in GP
(including Community Health Index number and date of administration) are recorded to enable reimbursement.
Information on individuals receiving LAIV in schools is collated in the Child Health Services Programme/Scottish
Immunisation & Recall Service database and was extracted for this analysis.21 Vaccination was used to define
exposure status when it was given at a time point between 1 September and the end of the influenza season
(see Figure 2). An individual was defined as vaccinated 14 days after the seasonal influenza vaccine had been
administered.29 The time period from the first day of the influenza season to day 14 post vaccination was
defined as ‘unexposed’ and the period from day 14 post vaccination until the end of the influenza season
was defined as ‘exposed’. Therefore, those people vaccinated between the start of the pre-influenza
period up until 14 days before the influenza season were defined as ‘exposed’ for the duration of the
influenza season.30
Study outcomes
Real-time reverse-transcription polymerase chain reaction
Data are collated by Health Protection Scotland (HPS) on patients having had swab samples RT-PCR tested
in primary and secondary care for routine diagnostic purposes outside the Sentinel scheme. All RT-PCR data
on both positive and negative tests are held by HPS in the national laboratory database (the ECOSS database).
From 1999, the RT-PCR testing used to confirm respiratory virus type has been found to be highly sensitive for
influenza A (H3, H1) and B diagnosis.3,31 Improvements to RT-PCR, since 2003, include the development of
multiplex testing, which increases the number of pathogens tested per assay. However, the high sensitivity of





























FIGURE 2 Relationship of the first influenza season (2010–11) to pre-, post- and non-influenza season periods.
Reproduced from Simpson et al.3 This is an Open Access article distributed in accordance with the terms of the
Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon
this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/
licenses/by/4.0/. The text below includes minor additions and formatting changes to the original text.
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Primary care practices involved in the HPS Sentinel swabbing scheme are encouraged to obtain nasal/throat
swabs from patients of all ages who have symptoms suggestive of influenza. Each GP was requested to
submit five swab samples per week (seven in season 2015/16) to the West of Scotland Specialist Virology
Centre (WoSSVC), Glasgow Royal Infirmary, for RT-PCR testing for a range of respiratory pathogens on any
patient presenting for consultation in the practice with influenza symptoms across all ages, independent of
whether the patient has or has not been vaccinated. The WoSSVC is a World Health Organization-accredited
national influenza centre, which participates in the quality assurance programme to maintain this status.




Age, sex SMR0127 and GP27
Hospital admission type: emergency/routine
admission
Date of first admission
Length of stay
SMR0127
Clinical condition codinga Influenza vaccination GP27
Recorded given Influenza vaccination ISD Scotland21
Clinical condition codinga Pneumococcal vaccination GP27
SIMD: rural/urbanb GP27
Prescription Antiviral prescriptions GP27
Prescription Asthma- and COPD-related prescriptions GP27
Clinical condition codinga Clinical at-risk groups (chronic respiratory disease,
chronic heart disease, chronic kidney disease,
chronic liver disease, chronic neurological disease,
immunosuppression, diabetes mellitus, pregnancy)
GP27
Diagnosis fields Charlson Comorbidity Index comorbidities SMR0127
Prescription, clinical attendance Number of previous GP consultations,
prescribed drugs
GP27
Clinical condition codinga Smoking,b exercise statusb GP27
Number of previous hospital admissions SMR0127
Clinical condition codinga Pregnancy GP27
Quality and Outcomes Framework exception
reported (patient unsuitable, etc.)
GP27
Clinical condition codinga Home oxygen GP27
Clinical condition coding,a diagnosis Trauma SMR0127 and GP27
Clinical condition coding,a diagnosis ILI SMR01,27 GP27 and
death records27
Clinical condition coding,a diagnosis Asthma and COPD symptoms and exacerbations SMR0127 and GP27
RT-PCR swab results ECOSS virology
database
COPD, chronic obstructive pulmonary disease; SIMD, Scottish Index of Multiple Deprivation.
a Clinician condition coding: Read/ICD-10 codes.
b Variable with possible missing data.
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Non-specific clinical outcomes
To determine the effect of vaccination status on influenza-related primary care consultations, hospital
admissions and deaths, secondary analyses were undertaken using non-specific clinical outcomes derived
from primary and secondary care. Data on ILI consultation were derived from the GP database. Data on
hospitalisation and cause of death from influenza or pneumonia were derived from SMR01.
Confounding factors
Key characteristics of each identified patient characteristics present in each season of the cohort were
included as confounders in the analyses. These were defined in each year on the first day of the
pre-influenza season (i.e. on 1 September).
Demographics
Sex, age band and socioeconomic status were included in all analyses; socioeconomic status was measured
using quintiles of the Scottish Index of Multiple Deprivation (SIMD). SIMD is an area-based measure of
deprivation derived from seven domains, including income, employment and education.3,33 SIMD identifies
small-area concentrations of multiple deprivation across all of Scotland in a consistent way. SIMD ranks
small areas (called data zones) from the most deprived (ranked 1) to the least deprived (ranked 6976),
and this was mapped onto postcode and then split into quintiles of socioeconomic status. For this project,
SIMD was derived from an individual patient’s full postcode. Rurality in terms of urban/rural location
(one large urban and eight remote rural areas) was also included in the analysis, and this was classified
in this project using an individual patient’s postcode.34
At-risk groups
At-risk patients are those with certain comorbidities for whom seasonal influenza vaccination is indicated.
Patients were defined as high risk according to national guidance if they had one or more of the
following conditions:28
l asthma
l chronic heart disease
l chronic kidney disease (including renal transplantation), stages 1 and 2 and 3–5
l chronic liver disease
l chronic neurological diseases
l chronic respiratory diseases
l conditions or drugs causing impaired immune function
l diabetes mellitus.
Chronic diseases
This was included for our non-specific clinical outcomes and adverse events. Comorbidity was defined by
the 17 disease categories that constituted the Charlson Comorbidity Index.35 This index has been validated
in a number of different databases using codes from health-care databases.36 A study has mapped Read
codes from a UK GP database to the relevant Charlson Comorbidity Index comorbid disease groups,
resulting in a model that performed well in the prediction of 5-year mortality.37 These codes were used to
identify comorbidities that are present in a patent’s record prior to the start of each pre-influenza season
(i.e. on 1 September).
Smoking status
Smoking status was derived from primary care data (current smoker, ex-smoker, non-smoker) and
determined on 1 September each year.
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Previous vaccinations
A variable was included for patients who have received seasonal influenza vaccination in previous seasons
to account for the possibility of persisting vaccine effectiveness in the subsequent year.38,39 Adjustment for
previous pneumococcal vaccination at any time in the primary care record prior to 1 September each year
was also undertaken.
Previous health-care utilisation
Measures of previous health-care resource use was used to capture other aspects of chronic health status
and included previous years’ GP consultations, prescriptions (repeat) and number of admissions to hospital.
Functional status
There is no direct measure of functional status made in any of these national databases. However, individuals
who were resident in some form of institutional care setting were identified from the primary care database.
This was used as an indicator of more severe functional limitation.
Sensitivity analyses
Simonsen et al.’s40 framework was used to consider the role of confounding.
Seasonality
Vaccine effectiveness should be highest during the influenza season and lower pre and post season
(see Figure 2).
Vaccine match
Vaccine effectiveness should be lower in years during which the influenza vaccine was a poor match for
the circulating virus.
Severity of influenza season
Vaccine effectiveness should be greater in years during which the circulating virus caused a large excess
mortality during the influenza season.
Age
It is thought that influenza vaccine is less effective in the oldest age groups because of immune
senescence.
Specificity of outcome measure
Vaccine effectiveness should be greatest for the most specific outcome (i.e. laboratory-confirmed influenza
infection) and lowest for the less specific outcomes [e.g. general practice acute respiratory infection (ARI)
consultations].
Unmeasured confounding
The robustness of the results were assessed by modelling the effect of an unmeasured confounder, such as
frailty, on the vaccine effectiveness estimates in a sensitivity analysis; an approach adopted to help explain
the role of unknown confounding in observational analyses.40 Three factors were varied: (1) the prevalence
of the confounder in the vaccinated population, (2) its prevalence in the unvaccinated population and
(3) the increased risk of the outcome attributable to the confounder.41
METHODS
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Instrumental variable analyses
The use of influenza vaccine coverage by geographical area has been found to be a strong and valid
instrumental variable, which can be used to account for confounding.3,42 Rather than comparing patients
with respect to whether or not they received influenza vaccination, this instrumental variable behaves like
natural randomisation of patients to regional vaccination groups that differ in their likelihood of receiving
influenza vaccination. The NSS TRE is an important development in this respect, and permissions were
received to extract granular postcode/geocoding data required to test the validity of this instrumental
variable analysis in the Seasonal Influenza Vaccination Effectiveness II (SIVE II) database. Therefore, the
use of vaccination uptake in geographically distinct CHP areas or other suitable health board areas as a
suitable instrumental variable was explored. Because there are only 14 health boards and > 30 CHPs, the
latter was used as the geographical area. To be valid, this instrumental variable needed to be related to
exposure status (i.e. vaccination status) and not have an independent effect on outcome other than by
ways mediated through the exposure.43 Furthermore, the instrumental variable should not be related to
any variables that confound the relationship between exposure and outcome. If an association with
confounders is demonstrated, it is assumed that the instrumental variable is associated with unmeasured
confounders and is therefore not valid. If the instrumental variable fulfils these criteria, it can be used in
analyses to produce unbiased estimates of vaccine effectiveness by accounting for unmeasured confounding.
Adverse events associated with vaccination
A self-controlled study design was used to estimate the risk of adverse events associated with influenza
vaccination.44 The assumption underlying this design is that in the situation in which the adverse event is
related to vaccination, the occurrence of an adverse event in the period after vaccination is greater than
periods in the same patient that are temporally unrelated to vaccination.45 This method has the advantage
of controlling for all fixed individual-level confounders as comparisons are within the same individual,
rather than between vaccinated and unvaccinated populations. The time period at risk for an adverse event
(risk interval) and time period not at risk (control interval) were determined separately for each outcome.46
For virtually all adverse events, the at-risk period was 14 days following receipt of the vaccination and the
pre-risk period was the 90-day period prior to the 14 days before the vaccine (i.e. days 104 to 15 before
receipt of the vaccine). The post-risk period was also 90 days and began on day 15 following vaccination.
The main comparisons are with the rate of adverse events in the risk period compared with (1) the pre-risk
period and (2) the post-risk period.
The self-controlled case series design uses data from only those with the adverse event and who are
vaccinated. For some of the adverse events, there is the possibility of a temporal change in the risk over the
≥ 200 days of observation periods. To take this into account, data were also included from unvaccinated
individuals who experienced the adverse event. These individuals were assigned a pseudo date of vaccination
based on the median date of vaccination for the age and season. Interaction tests were then used to compare
the rates of adverse events in (1) the risk period compared with the pre-risk period, and (2) the risk period
compared with the post-risk period, among vaccinated and unvaccinated individuals. If there is evidence of
a significant interaction with a higher risk ratio among vaccinated individuals, then this suggests that there
is a potential adverse event associated with vaccination. Because there were a large number of adverse events
being tested, the Benjamini–Hochberg false discovery rate was used to adjust for multiple testing.
The analysis of the self-controlled case series was undertaken using a stratified analysis in which the
comparisons of the different risk periods were made within individuals. This was achieved by using matched
logistic regression, with an offset for the length of the risk period. To avoid biases, the risk periods were not
censored at death or when an individual left a practice.
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Statistical analysis
A 5% significance level was used for hypothesis tests for the primary outcome. All p-values were two sided.
All analyses were undertaken in R, version 3.2.3 (The R Foundation for Statistical Computing, Vienna,
Austria). Ninety-five per cent confidence intervals (CIs) were also calculated. Logistic regression was used to
investigate vaccine uptake. A generalised additive model was used to estimate the vaccine effect within the
TND. Splines were used to model the effect of age and time within the season. A time-dependent Cox
model was used to estimate the effect of vaccination on the consultation, hospitalisation and mortality end
points. The receipt of vaccination was a time-dependent covariate. Summary statistics for this analysis are
based on the person-time at risk.
Annual and pooled analyses
The study initially analysed each of the six influenza seasons separately for the primary outcome.
However, a pooled analysis was carried out, in which increased precision was required (particularly for
analysing subgroups of patients). In the TND, the pooled analysis used a separate spline term for days
within each season.
Vaccine uptake and vaccine effectiveness
Vaccine uptake was calculated for all age groups per season as a percentage uptake.
Real-time reverse-transcription polymerase chain reaction outcomes
For vaccine effectiveness, using information from linked virological RT-PCR swab data (a binary event), a
nested case test-negative control study was carried out.47 Influenza positivity was compared with no influenza
among patients who had influenza-like symptoms. The primary analysis utilised a logistic generalised additive
model, in which the effects of sex, age, socioeconomic status (via the SIMD) and being in an at-risk morbidity
group were adjusted for (TND study).3,33 A spline function for time during each season was included to model
the background rate of influenza and correct for any potential bias associated with the proportions of
test-negative and test-positive patients in different periods. Vaccine effectiveness was measured by comparing
the results from swabs taken after vaccination among those patients vaccinated, with swabs taken from
those unvaccinated patients at the time the swab was collected. Vaccination was used to define exposure
status if it was given at a time point between 1 September and the end of the influenza season (see Figure 2).
The adjusted estimate of vaccine effectiveness was calculated using (1 –OR) × 100, in which the odds ratio
(OR) was derived from the coefficient of vaccine status in the model. In the main analysis, the first dose was
assessed only when two doses were given. An analysis, stratified by influenza A (H1, including pandemic
influenza and H3 subtype where recorded) and influenza B, was carried out.
In addition, a number of sensitivity analyses for the primary end point were carried out.
Non-Sentinel versus Sentinel
We explored the validity of using laboratory-confirmed influenza tests from non-Sentinel primary care and
secondary care sources compared with Sentinel primary care practices. Patient characteristics of individuals
swabbed in non-Sentinel primary care practices and secondary care were described and any interaction
between the source of the swab and the outcome was tested.
Negative controls
The use of laboratory-confirmed infections (currently 10 respiratory viruses and an infection, including
rhinovirus and adenovirus) was explored using multiplex RT-PCR at the same time as the influenza RT-PCR.
Non-specific clinical outcomes
Vaccine effectiveness was estimated for non-specific clinical outcomes: primary care consultations for ILI
and ARI; and emergency hospitalisation and death due to influenza/pneumonia. Hospital admissions and
consultations can have multiple events and each event was counted.
METHODS
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Methods that were found in previous studies to be optimal for measuring vaccine effectiveness and
accounting for bias and confounding were adopted.30,47,48 Adjusted risk ratios (RRs) of vaccine effectiveness
for prevention of hospitalisation/death/GP consultation were derived from time-dependent Cox models,
taking into account the time at risk and the possibility of multiple events (not for death). Models did not
include a cluster term to account for intrapractice correlation, as a practice code was not available in the
analysis. Practice code not being available ensures that the identity of the practices in the study is hidden
from the researchers. The models adjusted for sex, age, deprivation and clinical risk group, and exposure to
vaccination in each season was included as a time-dependent covariate. For each season, individuals began
in the unvaccinated group (and accumulated time at risk) until 14 days after the receipt of the vaccine, and
then they switched to the vaccinated group.
In all models used to estimate the vaccine effectiveness, variables associated with the receipt of a vaccination
and effect modifiers, such as vaccinations, consultations and hospitalisation in the previous influenza season,
SIMD, urban/rural status, smoking status and Charlson Comorbidity Index score, were adjusted for. The main
analysis for the non-specific clinical outcomes was a covariate adjustment.
Sample size
A final total sample size of up to 1.25 million people, from 230 practices, was expected. Using data from
the Pandemic Influenza Primary Care Reporting (PIPER) 2014/15 study cohort, which had 263,000 individuals
(of whom 16% were aged 2–17 years and 18% were aged ≥ 65 years),49 vaccine uptake among children
aged 3–12 years was 60% and vaccine uptake among people aged ≥ 65 years was 70%. Linked to this
PIPER cohort from all virology tests in Scotland were, overall, 1745 RT-PCR tests, comprising 331 RT-PCR
tests among 2- to 17-year-olds and 366 RT-PCR tests among people aged ≥ 65 years. This gave a multiplier
ratio of around 5 : 1 from the PIPER cohort to the SIVE II cohort, and this was used to estimate the number
of RT-PCR tests expected each year. This study expected 1800 RT-PCR tests per year among people aged
≥ 65 years and 1650 laboratory tests per year among children aged 2–17 years. The study expected 630
(i.e. 1745/12 × 5) asthma patients swabbed per year, because approximately 12% of the population was
treated for asthma.
Using data generated from the Seasonal Influenza Vaccine Effectiveness in the community (SIVE) project, the
study estimated a vaccination rate of 60% among children targeted for receipt of LAIV and a swab positivity
rate of 20% among unvaccinated children.13 This gave 90% power to detect a vaccine effectiveness of 31%
based on 1650 swabs in one season. Pooling data over two seasons gave an estimated 3300 swabs in
children eligible for vaccination and a 90% power to detect a vaccine effectiveness of 22%.
For those people aged ≥ 65 years targeted for receipt of TIV, for whom there was a vaccination rate of 70%
and a swab positivity rate of 10%, among the unvaccinated individuals the study anticipated an 80% power
to detect a vaccine effectiveness of 39%. It was estimated that there would be a need for 1800 swabs each
year in the later years. During the peak influenza activity, when swab positivity might have increased to
20%, there is a 90% power to detect a vaccine effectiveness of 31%. Approximately 1 in 12 of the
population is treated for asthma and it is anticipated that 1260 swabs are needed among patients with
asthma in the final two seasons.50 Assuming that 40% are vaccinated and that the swab positivity is around
15% gives 80% power for a vaccine effectiveness of 35%. These powers do not take into account design
effects for the clustering of patients within GPs. Analyses of the historic PIPER cohorts has revealed a design
effect of < 7% and this serves to increase the detectable vaccine effectiveness by about 2 percentage points.
Ethics and governance processes
Permissions were obtained from the Privacy Advisory Committee (NSS) (68/14), the National Research Ethics
Committee West Midlands – Edgbaston (15/WM/0035), the National Caldicott Guardian and General
Practice Data Custodians. Ms Elisabeth Ehrlich was the study’s public and patient involvement lead and
helped with the grant application. From a lay perspective, Ms Ehrlich helped to guide the team, ensuring
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that the work was relevant to the interests and needs of the public and patients. The study was supported
by members of the Asthma UK Centre for Applied Research Patient Advisory Group, which comprises
> 60 people (including parents of children). This group helped advise on, and contribute to, study materials
and it was invited to comment on the study from the patient and family perspective. An Independent Steering
Group was convened, with public and patient involvement, to oversee this work, which comprised Neil Kelly
(Chairperson, General Practitioner), Jonathan Van Tam (Professor of Health Protection), Punam Mangtani
(Associate Professor Clinical) and Elisabeth Ehrlich (Public and Patient Involvement Representative).
METHODS




The uptake of LAIV among the children registered with the 230 practices taking part in this project increased
over the study period (Table 2), with nearly two-thirds of primary school-aged children vaccinated by 2015/16.
TIV uptake among at-risk patients aged 12–65 years was highest in those aged 55–64 years, with nearly
two-thirds being vaccinated. Among those aged ≥ 65 years, vaccine uptake was highest in the 75–84 years
age group.
In all but two age groups (i.e. 2–4 and ≥ 85 years), more females than males received the influenza vaccine.
High levels of vaccine uptake were found among the least deprived children, people living in remote and
rural areas of Scotland, people with chronic diseases, people with an emergency hospital admission in the
past year (specifically for preschool-aged children and 11- to 17-year-olds), and people with a prior ARI GP
consultation in the past year (Table 3). The least deprived at-risk 18- to 55-year-olds were less likely to
receive the vaccine. For all those people aged ≥ 65 years and eligible to receive TIV, levels of uptake were
similar to levels among children, with higher levels of uptake among the least deprived groups, those people
living in rural and remote areas, those people with comorbidities and a prior ARI GP consultation. Those
people with an emergency hospitalisation in the last year were less likely to receive the vaccine.
Laboratory-confirmed influenza
Live attenuated influenza vaccine effectiveness
A statistically significant adjusted vaccine effectiveness among children (aged 2–11 years) for preventing
RT-PCR laboratory-confirmed influenza was found in 2015/16 [for all influenza, influenza A, influenza B
and the significant dominant influenza A(H1N1) subtypes]. This was not, however, evident in 2014/15
(Table 4). Vaccine effectiveness was higher for influenza B than for influenza A subtypes. There were
insufficient numbers of children receiving a second dose of LAIV to include in the statistical model.
TABLE 2 Vaccine uptake (%) by age group
Season
Age group (years)
2–4a 5–11a 12–17b 18–54b 55–64b 65–74 75–84 ≥ 85
2010/11 – – 21.74 29.97 62.78 60.40 66.20 62.62
2011/12 – – 21.64 30.29 63.19 60.65 66.93 63.65
2012/13 – – 22.32 30.69 63.48 61.40 67.74 64.90
2013/14 32.20c – 23.55 30.62 63.53 61.87 68.54 65.98
2014/15 39.33 58.76 24.94 29.52 61.70 61.16 67.95 65.25
2015/16 40.12 59.61 23.84 28.15 59.90 59.26 67.06 65.33
a LAIV percentage uptake.
b Percentage uptake for age group with at-risk morbidity.
c Only 2- to 3-year-olds were targeted for vaccination.
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TABLE 3 Adjusted ORs of differences in vaccine uptake by patient characteristics by age group (2010–16)
Variable
Age group (years), OR (95% CI)
2–4 5–11 11–17a 18–54a 55–64a 65–74 75–84 ≥ 85
Males (vs. females) 1.01 (0.98 to 1.03) 0.96 (0.95 to 0.97) 0.90 (0.86 to 0.95) 0.59 (0.58 to 0.59) 0.85 (0.83 to 0.87) 0.87 (0.86 to 0.88) 0.95 (0.94 to 0.97) 1.03 (1.00 to 1.06)
SIMD quintile
2 (vs. 1) 1.10 (1.06 to 1.14) 1.07 (1.05 to 1.09) 1.10 (1.02 to 1.19) 0.96 (0.94 to 0.98) 1.01 (0.98 to 1.05) 0.95 (0.93 to 0.97) 0.96 (0.93 to 0.98) 0.97 (0.93 to 1.02)
3 (vs. 1) 1.25 (1.21 to 1.30) 1.17 (1.14 to 1.19) 1.02 (0.94 to 1.10) 0.92 (0.90 to 0.94) 1.01 (0.98 to 1.05) 1.00 (0.98 to 1.02) 0.96 (0.93 to 0.99) 0.92 (0.88 to 0.97)
4 (vs. 1) 1.42 (1.37 to 1.47) 1.23 (1.21 to 1.26) 1.22 (1.13 to 1.32) 0.91 (0.89 to 0.93) 1.00 (0.97 to 1.04) 1.03 (1.01 to 1.06) 1.08 (1.04 to 1.11) 1.02 (0.98 to 1.07)
5 (vs. 1)b 1.76 (1.70 to 1.82) 1.46 (1.43 to 1.49) 1.36 (1.26 to 1.47) 0.86 (0.84 to 0.88) 1.00 (0.96 to 1.03) 1.13 (1.11 to 1.16) 1.19 (1.16 to 1.23) 1.22 (1.17 to 1.27)
UR8FOLD
UR8FOLD 2 (vs. 1)c 1.01 (0.99 to 1.04) 1.24 (1.22 to 1.26) 0.79 (0.75 to 0.84) 0.84 (0.82 to 0.85) 0.84 (0.81 to 0.87) 1.10 (1.09 to 1.12) 1.00 (0.98 to 1.02) 1.02 (0.99 to 1.05)
factor(UR8FOLD)3
(vs. 1)
1.03 (0.98 to 1.07) 1.32 (1.29 to 1.36) 0.82 (0.75 to 0.89) 0.90 (0.88 to 0.93) 0.88 (0.85 to 0.92) 1.07 (1.05 to 1.10) 0.94 (0.91 to 0.97) 0.79 (0.76 to 0.83)
factor(UR8FOLD)4
(vs. 1)
0.89 (0.83 to 0.95) 1.22 (1.17 to 1.27) 0.92 (0.79 to 1.06) 0.74 (0.70 to 0.78) 0.59 (0.55 to 0.63) 0.86 (0.83 to 0.89) 0.92 (0.88 to 0.96) 0.89 (0.83 to 0.95)
factor(UR8FOLD)5
(vs. 1)
1.09 (0.99 to 1.20) 1.64 (1.55 to 1.75) 1.12 (0.92 to 1.35) 0.98 (0.92 to 1.05) 1.00 (0.91 to 1.10) 0.67 (0.64 to 0.70) 0.68 (0.64 to 0.72) 0.72 (0.66 to 0.79)
factor(UR8FOLD)6
(vs. 1)
1.15 (1.10 to 1.20) 1.27 (1.24 to 1.30) 0.93 (0.85 to 1.01) 0.90 (0.87 to 0.92) 0.84 (0.81 to 0.87) 1.19 (1.17 to 1.22) 1.30 (1.26 to 1.34) 1.50 (1.42 to 1.58)
factor(UR8FOLD)7
(vs. 1)
1.18 (1.10 to 1.28) 1.26 (1.20 to 1.32) 1.24 (1.08 to 1.42) 0.99 (0.94 to 1.04) 0.78 (0.73 to 0.83) 1.10 (1.07 to 1.14) 1.17 (1.11 to 1.23) 1.48 (1.36 to 1.61)
factor(UR8FOLD)8
(vs. 1)














Age group (years), OR (95% CI)
2–4 5–11 11–17a 18–54a 55–64a 65–74 75–84 ≥ 85
Asthma vs. no asthma 1.94 (1.76 to 2.15) 1.69 (1.64 to 1.74) 1.92 (1.65 to 2.23) 1.35 (1.31 to 1.39) 1.33 (1.29 to 1.37) 2.70 (2.63 to 2.77) 2.73 (2.63 to 2.84) 2.33 (2.19 to 2.47)
Chronic heart disease
vs. no chronic heart
disease
1.68 (1.49 to 1.90) 1.70 (1.58 to 1.84) 2.48 (2.13 to 2.89) 2.64 (2.55 to 2.73) 2.31 (2.24 to 2.39) 2.99 (2.92 to 3.06) 3.14 (3.06 to 3.22) 2.77 (2.68 to 2.87)
Chronic liver disease
vs. no chronic liver
disease
2.45 (0.53 to 11.24) 1.74 (0.97 to 3.12) 9.35 (4.98 to 17.54) 1.78 (1.69 to 1.88) 1.48 (1.38 to 1.58) 1.90 (1.75 to 2.06) 2.08 (1.84 to 2.35) 1.30 (1.03 to 1.64)
Chronic neurological
disease vs. no chronic
neurological disease
2.03 (1.29 to 3.20) 1.84 (1.43 to 2.36) 2.19 (1.66 to 2.89) 2.08 (1.99 to 2.18) 1.57 (1.51 to 1.64) 2.09 (2.03 to 2.15) 2.24 (2.17 to 2.31) 2.14 (2.05 to 2.22)
COPD vs. no COPD 1.02 (0.06 to 16.41) 0.70 (0.33 to 1.46) 0.93 (0.80 to 1.10) 0.78 (0.76 to 0.81) 0.79 (0.76 to 0.82) 1.18 (1.13 to 1.24) 1.10 (1.04 to 1.15) 0.95 (0.87 to 1.03)
Diabetes mellitus vs.
no diabetes mellitus









1.10 (1.06 to 1.14) 1.02 (0.98 to 1.06) 3.75 (2.67 to 5.27) 2.57 (2.42 to 2.74) 2.01 (1.84 to 2.19) 0.81 (0.79 to 0.82) 0.73 (0.72 to 0.74) 0.75 (0.74 to 0.77)
Total number of ARI
GP consultations
per yeard
1.16 (1.13 to 1.19) 1.10 (1.07 to 1.12) 1.24 (1.15 to 1.35) 1.11 (1.09 to 1.13) 0.98 (0.95 to 1.00) 1.37 (1.33 to 1.40) 1.36 (1.31 to 1.41) 1.32 (1.25 to 1.39)
COPD, chronic obstructive pulmonary disease; UR8FOLD, Urban Rural Score.
a At-risk group.
b 5 = least deprived.
c 1 = large urban; 8 = remote rural.








































































































































































TABLE 4 Vaccine effectiveness for laboratory-confirmed influenza for LAIV in 2- to 11-year-olds
Influenza type and subtype
Laboratory-confirmed influenza
Total positive (%)
Vaccine effectiveness (95% CI)











Influenza Ac 44/131 33.59 342/1272 26.89 9.34 11.09 (–33.87 to 40.95) 11.36 (–35.31 to 41.93)
A(H1N1) 3/4 75.00 383/1399 27.38 0.29 –474.59 (–5469.42 to 40.72) –468.38 (–5949.37 to 46.60)
A(H3) 33/109 30.28 353/1294 27.28 7.77 27.04 (–14.77 to 53.62) 30.67 (–10.95 to 56.68)
Influenza B 3/18 16.67 383/1385 27.65 1.28 62.50 (–31.42 to 89.30) 69.56 (–9.04 to 91.50)
Influenza positived 47/149 31.54 339/1254 27.03 10.62 18.72 (–19.91 to 44.91) 20.54 (–18.53 to 46.73)
Season: 2015/16
Influenza Ac 42/176 23.86 410/1513 27.10 10.42 51.62 (28.95 to 67.06) 46.38 (19.77 to 64.16)
A(H1N1) 36/143 25.17 416/1546 26.91 8.47 46.27 (18.90 to 64.40) 40.39 (8.21 to 61.29)
A(H3) 1/5 20.00 451/1684 26.78 0.30 100.00 (–inf to 100.00) 100.00 (–inf to 100.00)
Influenza B 5/43 11.63 447/1646 27.16 2.55 82.86 (50.51 to 94.07) 88.27 (63.86 to 96.19)
Influenza positived 46/217 21.20 406/1472 27.58 12.85 57.71 (39.45 to 70.46) 58.09 (39.08 to 71.17)
–inf, infinity.
a Adjusted for time (days) only.
b Adjusted for time (days), age, clinical risk groups and swab location (i.e. hospital or GP).
c Influenza A subtyped + unsubtyped.













Trivalent influenza vaccine effectiveness
Among at-risk 18- to 64-year-olds, a significant TIV effectiveness was found for four of the six seasons
(Table 5). For the two seasons with no significant vaccine effectiveness, low levels of circulating influenza
virus were present (2011/12, 5%; 2013/14, 9%). Unlike the pattern in children, there was an inconsistent
observation of vaccine effectiveness being greater against B subtypes of influenza than against A subtypes
of influenza. Among those people aged ≥ 65 years, significant vaccine effectiveness of 57% was found for
the 2013/14 season (Table 6); however, no other season had significant vaccine effectiveness. No obvious
pattern of vaccine effectiveness by influenza subtype was evident between the seasons.
At-risk comorbidity vaccine effectiveness
A pooled analysis over six seasons found a significant positive vaccine effectiveness for preventing RT-PCR
laboratory-confirmed influenza for those aged people ≥ 65 years with asthma (Table 7). Significant positive
vaccine effectiveness was found for preventing laboratory-confirmed influenza A among those people
aged ≥ 65 years with chronic heart disease. Generally, vaccine effectiveness was non-statistically higher
against influenza B than against influenza A.
An analysis of age groups found significant vaccine effectiveness for (1) 18- to 54-year-olds with asthma,
impaired immune function and a body mass index (BMI) of > 25 kg/m2 (Table 8); (2) 55- to 64-year-olds with
asthma (Table 9); (3) 65- to 74-year-olds with asthma and chronic kidney disease (overall and for influenza A)
(Table 10); and (4) 75- to 84-year-olds with chronic respiratory disease [against influenza A(H3N2)] and
asthma (against influenza B) (Table 11). Among the oldest age group (i.e. those people aged ≥ 85 years),
significant vaccine effectiveness was found for those with chronic respiratory disease (overall and for
influenza A and B), chronic heart disease (overall), asthma [overall, for influenza A and B, and for influenza A
(H3N2)], diabetes mellitus (overall and for influenza A) and impaired immune function (overall) (Table 12).
Swabbing setting
No significant difference was found in vaccine effectiveness between laboratory-confirmed influenza tests
from Sentinel GPs, non-Sentinel GPs and hospital care sources (Table 13). No interaction was found
between the source of the swab and the outcome.
Negative controls
The study explored the use of laboratory-confirmed infections, tested using multiplex RT-PCR at the same time
as the influenza RT-PCR, and found no significant vaccine effectiveness for non-influenza viruses (Table 14).
Clinical outcomes
After adjustment for confounding, including age in the model, significant negative vaccine effectiveness
was found for GP outcomes, ARI and ILI for people aged ≥ 65 years (Table 15). Significant positive vaccine
effectiveness was found for emergency hospitalisation or death from influenza and pneumonia (see Table 15).
Rates and relative risks can be found in Table 16.
In the sensitivity analysis, and according to Simonsen et al.’s framework,40 vaccine effectiveness during the
pre- and post-influenza season was similar to that during peak influenza season (Table 17). Little variation
was found between the seasons with different poorly or well-matched vaccines, severity, or by specificity
of outcome (all-cause mortality had higher vaccine effectiveness than hospitalisation for influenza
and pneumonia).37
Instrumental variable analysis
Vaccine uptake did vary by the proposed instrumental variable community CHP areas (Table 18). However,
the correlation with individual vaccine uptake and our outcome was low and, therefore, this is considered
a weak instrument. Therefore, it was not possible to use this method to estimate vaccine effectiveness
accounting for unmeasured confounding.
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Vaccine effectiveness (95% CI)
















Influenza Ac 39/118 33.05 156/380 41.05 23.69 46.03 (7.66 to 68.45) 45.34 (1.37 to 69.71)
A(H1N1) 33/104 31.73 162/394 41.12 20.88 51.25 (14.27 to 72.28) 49.01 (5.67 to 72.44)
A(H3) 0/0 NA 195/498 39.16 0.00 –1.62E–12 (–inf to 100.00) 0.00 (–inf to 100.00)
Influenza B 6/26 23.08 189/472 40.04 5.22 73.38 (29.90 to 89.89) 71.17 (22.61 to 89.26)
Influenza
positived




Influenza Ac 12/22 54.55 131/379 34.56 5.49 –34.00 (–236.15 to 46.58) –65.86 (–333.81 to 36.59)
A(H1N1) 0/0 NA 143/401 35.66 0.00 –4.66E–13 (–inf to 100.00) 0.00 (–inf to 100.00)
A(H3) 7/12 58.33 136/389 34.96 2.99 –47.99 (–401.76 to 56.35) –103.89 (–645.92 to 44.27)
Influenza B 0/0 NA 143/401 35.66 0.00 –2.52E–11 (–inf to 100.00) 0.00 (–inf to 100.00)
Influenza
positived






















Vaccine effectiveness (95% CI)













Influenza Ac 32/91 35.16 238/562 42.35 13.94 46.14 (12.98 to 66.66) 45.82 (10.59 to 67.16)
A(H1N1) 1/15 6.67 269/638 42.16 2.30 92.18 (39.64 to 98.99) 89.53 (17.41 to 98.67)
A(H3) 21/49 42.86 249/604 41.23 7.50 15.71 (–54.02 to 53.87) 22.60 (–46.92 to 59.23)
Influenza B 16/43 37.21 254/610 41.64 6.58 42.47 (–10.78 to 70.12) 33.19 (–31.48 to 66.05)
Influenza
positived





Influenza Ac 25/55 45.45 262/608 43.09 8.30 31.29 (–24.55 to 62.10) 25.41 (–42.75 to 61.02)
A(H1N1) 18/39 46.15 269/624 43.11 5.88 27.25 (–43.77 to 63.19) 37.50 (–27.22 to 69.29)
A(H3) 2/7 28.57 285/656 43.45 1.06 68.90 (–64.61 to 94.12) 46.91 (–205.10 to 90.76)
Influenza B 1/2 50.00 286/661 43.27 0.30 5.11 (–1482.68 to 94.31) 66.91 (–641.63 to 98.52)
Influenza
positived



















































































































































































Vaccine effectiveness (95% CI)















Influenza Ac 82/180 45.56 407/887 45.89 16.87 27.06 (–3.77 to 48.73) 31.47 (1.31 to 52.42)
A(H1N1) 5/9 55.56 484/1058 45.75 0.84 18.53 (–232.68 to 80.05) 23.21 (–219.16 to 81.53)
A(H3) 62/140 44.29 427/927 46.06 13.12 28.57 (–5.27 to 51.54) 29.84 (–4.80 to 53.03)
Influenza B 14/39 35.90 475/1028 46.21 3.66 62.08 (22.19 to 81.52) 64.95 (26.82 to 83.21)
Influenza
positived






Influenza Ac 55/149 36.91 434/1101 39.42 11.92 39.11 (11.26 to 58.21) 42.27 (14.87 to 60.84)
A(H1N1) 44/111 39.64 445/1139 39.07 8.88 30.00 (–6.47 to 53.97) 32.85 (–3.26 to 56.33)
A(H3) 2/4 50.00 487/1246 39.09 0.32 –227.57 (–12,600.90 to 91.55) –195,334.91 (–3.78E+26 to 100.00)
Influenza B 16/47 34.04 473/1203 39.32 3.76 54.53 (11.05 to 76.76) 41.12 (–19.54 to 70.99)
Influenza
positived
69/193 35.75 420/1057 39.74 15.44 41.51 (18.16 to 58.20) 40.88 (16.43 to 58.17)
–inf, infinity; NA, not applicable.
a Adjusted for time (days) only.
b Adjusted for time (days), age and swab location (i.e. hospital or GP).
c Influenza A subtyped + unsubtyped.























Vaccine effectiveness (95% CI)
















Influenza Ac 25/53 47.17 234/458 51.09 10.37 31.84 (–24.33 to 62.63) 42.76 (–13.13 to 71.03)
A(H1N1) 19/39 48.72 240/472 50.85 7.63 28.99 (–43.07 to 64.75) 28.18 (–53.73 to 66.45)
A(H3) 0/0 NA 259/511 50.68 0.00 0.00 (–inf to 100.00) 0.00 (–inf to 100.00)
Influenza B 14/28 50.00 245/483 50.72 5.48 41.79 (–33.29 to 74.58) 35.01 (–64.89 to 74.46)
Influenza
positived




Influenza Ac 15/23 65.22 280/475 58.95 4.62 –3.28 (–157.62 to 58.60) –6.80 (–187.75 to 60.89)
A(H1N1) 0/0 NA 295/498 59.24 0.00 0.00 (–inf to 100.00) 0.00 (–inf to 100.00)
A(H3) 8/12 80.00 287/488 58.81 2.01 –104.95 (–892.87 to 57.70) –87.17 (–867.16 to 63.78)
Influenza B 0/2 0.00 295/496 59.48 0.40 100.00 (–inf to 100.00) 100.00 (–inf to 100.00)
Influenza
positived



















































































































































































Vaccine effectiveness (95% CI)













Influenza Ac 78/134 58.21 450/818 55.01 0.48 –2.29 (–50.49 to 30.47) 13.95 (–31.48 to 43.68)
A(H1N1) 8/8 37.50 525/944 55.61 5.25 60.32 (–69.43 to 90.71) 64.10 (–69.39 to 92.39)
A(H3) 50/78 64.10 478/874 54.69 0.00 –38.27 (–126.17 to 15.47) –23.86 (–111.01 to 27.30)
Influenza B 29/53 54.72 499/899 55.51 2.02 14.98 (–51.13 to 52.17) 15.03 (–59.74 to 54.80)
Influenza
positived





Influenza Ac 31/53 58.49 618/1058 58.41 4.77 31.18 (–22.14 to 61.22) 55.47 (17.53 to 75.96)
A(H1N1) 24/39 61.54 625/1072 58.30 3.51 16.92 (–61.47 to 57.25) 39.51 (–22.62 to 70.16)
A(H3) 2/5 40.00 647/1106 58.50 0.45 69.14 (–89.40 to 94.97) 100.00 (–1187.54 to 100.00)
Influenza B 0/1 0.00 649/1110 58.47 0.09 100.00 (–inf to 100.00) 100.00 (–inf to 100.00)
Influenza
positived






















Vaccine effectiveness (95% CI)















Influenza Ac 282/488 57.79 1127/2037 55.33 19.33 12.11 (–9.10 to 29.21) 13.58 (–8.92 to 31.43)
A(H1N1) 9/12 75.00 1400/2513 55.71 0.48 –124.89 (–754.55 to 40.82) –145.32 (–1171.67 to 52.68)
A(H3) 224/393 57.00 1185/2132 55.58 15.56 15.96 (–6.05 to 33.39) 15.84 (–8.03 to 34.43)
Influenza B 54/84 64.29 1355/2441 55.51 3.33 –14.76 (–86.81 to 29.50) –1.82 (–76.04 to 41.11)
Influenza
positived






Influenza Ac 113/183 61.75 1264/2350 53.79 7.22 –5.26 (–44.95 to 23.57) 7.61 (–30.39 to 34.53)
A(H1N1) 81/133 60.90 1296/2400 54.00 5.25 1.47 (–42.04 to 31.66) 10.21 (–33.15 to 39.45)
A(H3) 2/3 66.67 1375/2530 54.35 0.12 –179.37 (–4614.03 to 83.44) –34.41 (–2046.34 to 91.58)
Influenza B 47/82 57.32 1330/2451 54.26 3.24 11.48 (–40.96 to 44.42) 4.02 (–57.78 to 41.61)
Influenza
positived
159/263 60.46 1218/2270 53.66 10.38 0.76 (–30.05 to 24.28) 7.31 (–23.73 to 30.57)
–inf, infinity; NA, not applicable.
a Adjusted for time (days) only.
b Adjusted for time (days), age and swab location (i.e. hospital or GP).
c Influenza A subtyped + unsubtyped.
















































































































































































Vaccine effectiveness (95% CI)













Influenza Ac 178/287 62.02 1332/2209 60.30 11.50 13.60 (–13.84 to 13.21) 13.21 (–14.46 to 34.19)
A(H1N1) 62/92 67.39 1448/2404 60.23 3.69 –0.92 (–61.95 to 37.11) –2.93 (–66.33 to 32.29)
A(H3) 79/132 59.85 1431/2364 60.53 5.29 12.09 (–31.45 to 41.21) 12.48 (–30.89 to 41.48)
Influenza B 39/62 62.90 1471/2434 60.44 2.48 15.38 (–48.88 to 51.91) 19.04 (–43.25 to 54.24)
Influenza
positived
217/347 62.54 1293/2149 60.17 13.90 15.06 (–9.15 to 33.90) 15.72 (–8.43 to 34.50)
Chronic heart
disease
Influenza Ac 193/256 75.39 1249/1688 73.99 13.17 31.95 (4.22 to 51.65) 33.12 (5.72 to 52.56)
A(H1N1) 51/60 85.00 1391/1884 73.83 3.09 –33.65 (–182.87 to 6.86) –31.91 (–181.45 to 38.18)
A(H3) 94/128 73.44 1348/1816 74.23 6.58 36.47 (–1.44 to 60.21) 35.74 (–2.79 to 59.82)
Influenza B 42/50 84.00 1400/1894 73.92 2.57 1.58 (–122.38 to 56.44) 8.34 (–110.18 to 60.03)
Influenza
positived
232/303 76.57 1210/1641 73.74 15.59 28.71 (1.78 to 48.25) 30.88 (–4.45 to 49.94)
Asthma Influenza Ac 114/148 77.03 748/998 74.95 12.91 43.06 (6.27 to 65.41) 44.93 (8.73 to 66.77)
A(H1N1) 40/49 81.63 822/1097 74.93 4.28 12.72 (–95.99 to 61.13) 12.70 (–100.41 to 61.97)
A(H3) 54/65 83.08 808/1081 74.75 5.67 –14.47 (148.84 to 47.34) –3.95 (–128.44 to 52.69)
Influenza B 24/34 70.59 838/1112 75.36 3.06 65.33 (19.31 to 85.10) 66.34 (19.99 to 85.84)
Influenza
positived
137/181 75.69 725/965 75.13 7.07 48.77 (20.91 to 66.81) 50.69 (23.26 to 68.31)
a Adjusted for time (days) only.
b Adjusted for time (days), age and swab location (i.e. hospital or GP).
c Influenza A subtyped + unsubtyped.






















Vaccine effectiveness (95% CI)












Influenza Ac 27/74 36.49 182/496 36.69 12.98 20.12 (–45.75 to 56.22) 24.43 (–41.03 to 59.51)
A(H1N1) 11/32 34.38 198/538 36.80 5.61 31.01 (–84.47 to 74.20) 26.50 (–87.95 to 71.25)
A(H3) 9/26 34.62 200/544 36.76 4.56 30.75 (–86.64 to 74.30) 38.10 (–83.17 to 79.08)
Influenza B 6/20 30.00 203/550 36.91 3.51 61.28 (–24.82 to 87.99) 62.37 (–23.32 to 88.52)
Influenza
positived
33/94 35.11 176/476 36.97 16.49 27.59 (–22.60 to 57.24) 29.70 (–20.53 to 59.00)
Chronic heart disease Influenza Ac 12/29 41.38 86/204 42.16 12.45 24.83 (–104.11 to 72.31) 32.86 (–85.58 to 75.71)
A(H1N1) 5/14 35.71 93/219 42.47 6.01 –158.96 (–4645.69 to 85.87) 90.67 (–13,107.43 to 99.99)
A(H3) 5/10 50.00 93/223 41.70 4.29 18.20 (–1897.24 to 96.65) 100.00 (–7.08E+11 to 100.00)
Influenza B 6/10 60.00 92/223 41.26 4.29 31.84 (–430.94 to 91.25) 100.00 (–inf to 100.00)
Influenza
positived
16/37 43.24 82/196 41.84 15.88 4.15 (–116.09 to 57.49) 7.83 (–108.90 to 59.33)
Asthma Influenza Ac 72/280 25.71 546/1600 34.13 14.89 50.88 (32.30 to 64.36) 52.42 (33.50 to 65.95)
A(H1N1) 33/141 23.40 585/1739 33.64 7.50 49.47 (19.92 to 68.12) 55.98 (28.33 to 72.97)
A(H3) 22/83 26.51 596/1797 33.17 4.41 59.78 (29.76 to 76.97) 53.36 (17.59 to 73.61)
Influenza B 21/82 25.61 597/1798 33.20 4.36 58.40 (28.08 to 75.93) 62.41 (33.79 to 78.66)
Influenza
positived









































































































































































TABLE 8 Overall vaccine effectiveness for laboratory-confirmed influenza for various influenza types and subtypes in people aged 18–54 years in Scotland (2010–16) in various








Vaccine effectiveness (95% CI)










Chronic liver disease Influenza Ac 5/15 33.33 53/145 36.55 9.38 32.90 (–140.51 to 81.28) 37.88 (–130.17 to 83.24)
A(H1N1) 2/6 33.33 56/154 36.36 3.75 0.00 (–inf to 100.00) 0.00 (–inf to 100.00)
A(H3) 1/5 20.00 57/155 36.77 3.13 19.06 (–inf to 100.00) 0.00 (–inf to 100.00)
Influenza B 3/5 60.00 55/155 35.48 3.13 0.00 (–inf to 100.00) 100.00 (–inf to 100.00)
Influenza
positived
8/20 40.00 50/140 35.71 12.50 22.92 (–130.59 to 74.23) 32.61 (–109.70 to 78.34)
Chronic neurological
disease
Influenza Ac 12/14 64.29 52/109 47.71 11.38 –267.18 (–12,633.70 to 89.41) –4.24E+5 (–inf to 100.00)
A(H1N1) 4/9 44.44 57/114 50.00 7.32 79.30 (–52.98 to 97.20) 100.00 (–inf to 100.00)
A(H3) 1/1 100.00 60/122 49.18 0.81 –2.8E+11 (–inf to 100.00) 0.00 (–inf to 100.00)
Influenza B 0/2 0.00 61/121 50.41 1.63 100.00 (–inf to 100.00) 100.00 (–inf to 100.00)
Influenza
positived
9/16 56.25 52/107 48.60 13.01 60.34 (–74.89 to 91.00) 59.10 (–182.08 to 94.07)
Diabetes mellitus Influenza Ac 29/56 51.79 206/379 54.35 12.87 27.04 (–34.28 to 60.36) 30.00 (–30.15 to 62.35)
A(H1N1) 13/23 56.52 222/412 53.88 5.29 –3.30 (–171.77 to 60.73) 11.16 (–182.82 to 72.09)
A(H3) 11/19 57.89 224/416 53.85 4.37 –45.50 (–420.43 to 59.32) –48.82 (–447.01 to 59.51)
Influenza B 9/17 52.94 226/418 54.07 3.91 79.64 (11.24 to 95.33) 80.48 (–9.48 to 96.52)
Influenza
positived




















Vaccine effectiveness (95% CI)












Influenza Ac 6/20 30.00 88/234 37.61 7.87 80.71 (–25.42 to 97.03) 100.00 (–2.4E+10 to 100.00)
A(H1N1) 1/5 20.00 93/249 37.35 1.97 99.09 (–6.4E+8 to 100.00) 100.00 (–1.85E+13 to 100.00)
A(H3) 4/10 40.00 90/244 36.89 3.94 70.38 (–81.40 to 95.16) 64.44 (–121.43 to 94.29)
Influenza B 5/12 41.67 89/242 36.78 4.72 64.12 (92.08 to 4.72) 67.42 (–57.79 to 93.27)
Influenza
positived
11/32 34.38 83/222 37.39 12.60 66.46 (13.45 to 87.00) 67.51 (15.08 to 87.57)
Chronic kidney disease Influenza Ac 10/26 38.46 80/157 50.96 14.21 98.42 (74.77 to 99.90) 100.00 (–262E+23 to 100.00)
A(H1N1) 3/10 30.00 87/173 50.29 5.46 100.00 (–2.25E+25 to 100.00) 100.00 (–1.29E+30 to 100.00)
A(H3) 6/12 50.00 84/171 49.12 6.56 49.55 (–239.03 to 92.49) 92.70 (–182.86 to 99.81)
Influenza B 4/4 100.00 86/179 48.04 2.19 –1.26E+22 (–inf to 100.00) –1.21E+30 (–inf to 100.00)
Influenza
positived
14/30 46.67 76/153 49.67 16.39 52.28 (–30.13 to 82.50) 69.12 (–45.74 to 93.46)
eBMI > 25 kg/m2 Influenza Ac 6/45 15.56 75/267 28.09 14.42 70.94 (25.87 to 88.61) 78.52 (39.16 to 92.42)
A(H1N1) 6/31 19.35 76/281 27.05 9.94 60.15 (–10.00 to 85.56) 64.10 (–12.07 to 88.50)
A(H3) 1/1 100.00 81/311 26.05 0.32 0.00 (–inf to 100.00) 0.00 (–inf to 100.00)
Influenza B 3/14 21.43 79/298 26.51 4.49 65.65 (–63.58 to 92.79) 49.38 (–200.13 to 91.46)
Influenza
positived
9/58 15.52 73/254 28.74 18.59 65.04 (23.95 to 83.93) 68.35 (24.52 to 86.72)
–inf, infinity.
a Adjusted for time (days) only.
b Adjusted for time (days), season, age and swab location (i.e. hospital or GP).
c Influenza A subtyped + unsubtyped.
d Influenza A+ B.

















































































































































































Vaccine effectiveness (95% CI)













Influenza Ac 60/102 58.82 283/583 48.54 14.89 –7.33 (–73.60 to 33.65) –12.43 (–83.74 to 31.20)
A(H1N1) 26/44 59.09 317/641 49.45 6.42 –11.59 (–127.76 to 45.21) –22.93 (–157.48 to 41.31)
A(H3) 21/37 56.76 322/648 49.69 5.40 23.85 (–71.39 to 66.16) –5.09 (–142.55 to 54.47)
Influenza B 7/14 50.00 336/671 50.07 2.04 55.98 (–46.59 to 86.78) 60.06 (–35.65 to 88.24)
Influenza
positived
67/116 57.76 276/569 48.51 16.93 1.56 (–54.40 to 37.24) –1.72 (–60.85 to 35.67)
Chronic heart
disease
Influenza Ac 27/44 61.36 184/297 61.95 12.90 49.15 (–9.49 to 76.39) 49.09 (–9.66 to 76.37)
A(H1N1) 12/21 57.14 199/320 62.19 6.16 58.83 (–19.25 to 85.79) 61.84 (–16.59 to 87.51)
A(H3) 8/14 57.14 203/327 62.08 4.11 47.05 (–76.42 to 84.11) 47.66 (–77.55 to 84.57)
Influenza B 5/7 71.43 206/334 61.68 2.05 7.37 (–573.80 to 87.27) –2157.56 (–209,967.00 to 75.74)
Influenza
positived
32/51 62.75 179/290 61.72 14.96 41.64 (–18.00 to 71.14) 39.89 (–21.35 to 70.23)
Asthma Influenza Ac 42/75 56.00 265/494 53.64 13.18 30.80 (–19.82 to 60.03) 35.62 (–13.78 to 63.57)
A(H1N1) 17/32 53.13 290/537 54.00 5.62 35.26 (–63.07 to 74.29) 35.68 (–68.54 to 75.45)
A(H3) 18/29 62.07 289/540 53.52 5.10 8.52 (–138.11 to 64.85) 16.28 (–130.89 to 69.64)
Influenza B 12/15 13.33 305/554 55.05 2.64 92.95 (66.23 to 98.53) 94.77 (71.65 to 99.04)
Influenza
positived




















Vaccine effectiveness (95% CI)












Influenza Ac 5/12 41.67 32/60 53.33 16.67 82.66 (–140.51 to 81.28) 100.00 (–inf to 100.00)
A(H1N1) 1/4 25.00 36/68 52.94 5.56 100.00 (–inf to 100.00) 100.00 (–inf to 100.00)
A(H3) 4/7 57.14 33/65 50.77 9.72 61.95 (–737.95 to 98.27) 100.00 (–inf to 100.00)
Influenza B 0/2 0.00 37/70 52.86 2.78 100.00 (–inf to 100.00) 100.00 (–inf to 100.00)
Influenza
positived




Influenza Ac 19/28 67.86 83/159 52.20 14.97 –2.2E+17 (–2.16E+17 to 99.78) –6.7E+6 (–3.67E+17 to 100.00)
A(H1N1) 8/10 80.00 94/177 53.11 5.35 –8.3E+14 (–1.10E+10 to 100.00) –2.53E+12 (–inf to 100.00)
A(H3) 9/13 69.23 93/174 53.45 6.95 –1227.12 (–23,294.75 to 24.72) –1.43E+34 (–inf to 100.00)
Influenza B 2/3 66.67 100/184 54.35 1.60 –285.94 (–15,731.02 to 90.59) –2.65E+5 (–1.34E+29 to 100.00)
Influenza
positived
21/31 67.74 81/156 51.92 16.58 –524.31 (–2945.94 to 27.96) –1007.43 (–6944.49 to –74.09)
Diabetes
mellitus
Influenza Ac 39/59 66.10 187/306 61.11 16.16 32.65 (–45.22 to 68.77) 34.65 (–46.44 to 70.84)
A(H1N1) 14/24 58.33 212/341 62.17 6.58 –24.77 (478.667 to 73.10) 26.51 (–179.83 to 80.70)
A(H3) 16/23 69.57 210/342 61.40 6.30 0.04 (–233.25 to 70.02) 23.17 (–188.28 to 79.52)
Influenza B 3/6 50.00 223/359 62.12 1.64 100.00 (–inf to 100.00) 55.39 (–397.51 to 96.00)
Influenza
positived









































































































































































TABLE 9 Overall vaccine effectiveness for laboratory-confirmed influenza for various influenza types and subtypes in people aged 55–64 years in Scotland (2010–16) in various








Vaccine effectiveness (95% CI)













Influenza Ac 12/16 75.00 65/138 47.10 10.39 –106.35 (–807.45 to 53.08) –97.56 (–860.25 to 59.36)
A(H1N1) 3/4 75.00 74/150 49.33 2.60 100.00 (–inf to 100.00) 100.00 (–inf to 100.00)
A(H3) 7/8 87.50 70/146 47.95 5.19 –3.67E+82 (–inf to 100.00) –2.25E+68 (–inf to 100.00)
Influenza B 0/3 0.00 77/151 50.99 1.95 100.00 (–inf to 100.00) 100.00 (–inf to 100.00)
Influenza
positived
12/19 63.16 65/135 48.15 12.34 28.43 (–165.04 to 80.68) 27.79 (–193.54 to 82.24)
Chronic kidney
disease
Influenza Ac 20/29 68.97 110/158 69.62 15.51 32.90 (–79.79 to 74.96) 22.56 (–114.57 to 72.05)
A(H1N1) 6/10 60.00 124/177 70.06 5.35 67.92 (–553.88 to 98.43) –4.5E+19 (–inf to 100.00)
A(H3) 10/14 71.43 120/173 69.36 7.49 26.65 (–546.44 to 91.68) –8.52 (–901.07 to 88.24)
Influenza B 3/5 60.00 127/182 69.78 2.67 100.00 (–inf to 100.00) –1.6E+14 (–inf to 100.00)
Influenza
positived
23/33 69.70 107/154 69.48 17.65 74.94 (–21.45 to 94.83) 67.38 (–77.57 to 94.01)
eBMI > 25 kg/m2 Influenza Ac 9/20 45.00 72/134 53.73 12.99 62.18 (–7.14 to 86.65) 61.62 (–27.75 to 88.47)
A(H1N1) 6/13 46.15 75/141 53.19 8.44 56.94 (–55.13 to 88.05) 69.12 (–43.86 to 93.37)
A(H3) 1/1 100.00 80/153 52.29 0.65 0.00 (–inf to 100.00) 0.00 (–inf to 100.00)
Influenza B 2/2 100.00 79/152 51.97 1.30 0.00 (–inf to 100.00) 0.00 (–inf to 100.00)
Influenza
positived
11/22 50.00 70/132 53.03 14.29 57.20 (–19.30 to 84.65) 57.81 (–34.78 to 86.79)
–inf, infinity.
a Adjusted for time (days) only.
b Adjusted for time (days), season, age and swab location (i.e. hospital or GP).
c Influenza A subtyped + unsubtyped.
d Influenza A+ B.













TABLE 10 Overall vaccine effectiveness for laboratory-confirmed influenza for various influenza types and subtypes in people aged 65–74 years in Scotland (2010–16)








Vaccine effectiveness (95% CI)













Influenza Ac 90/142 63.38 591/1024 57.71 12.18 5.15 (–41.73 to 36.53) 6.96 (–39.56 to 37.98)
A(H1N1) 37/58 63.79 644/1108 58.12 4.97 6.54 (–67.71 to 47.92) 10.54 (–61.81 to 50.54)
A(H3) 35/51 68.63 646/1115 57.94 4.37 –59.82 (–215.67 to 19.09) –57.72 (–212.17 to 20.31)
Influenza B 20/30 66.67 661/1136 58.19 2.57 5.29 (–123.24 to 59.82) 12.59 (–110.36 to 63.68)
Influenza
positived
110/172 63.95 571/994 57.44 14.75 6.52 (–36.77 to 36.10) 9.21 (–33.29 to 38.16)
Chronic heart
disease
Influenza Ac 61/78 78.21 436/591 73.77 11.66 18.54 (–53.83 to 56.86) 22.75 (–46.68 to 59.32)
A(H1N1) 22/29 75.86 475/640 74.22 4.33 18.15 (–119.09 to 69.42) 41.19 (–72.66 to 79.97)
A(H3) 21/27 77.78 476/642 74.14 4.04 20.35 (–122.69 to 71.51) 21.11 (–121.12 to 71.86)
Influenza B 15/19 78.95 482/650 74.15 2.84 22.97 (–159.73 to 77.16) 29.22 (–145.98 to 79.64)
Influenza
positived
76/97 78.35 421/572 73.60 14.50 19.97 (–40.43 to 54.39) 23.50 (–34.88 to 56.62)
Asthma Influenza Ac 49/71 69.01 343/465 73.76 13.25 51.09 (4.24 to 75.02) 52.41 (6.50 to 75.78)
A(H1N1) 22/30 73.33 370/506 73.12 5.60 49.37 (–33.86 to 80.85) 51.88 (–32.58 to 82.53)
A(H3) 18/24 75.00 374/512 73.05 4.48 –3.42 (–225.38 to 67.13) 0.43 (–212.35 to 68.26)
Influenza B 12/13 61.54 384/523 73.42 2.43 62.96 (–25.05 to 89.03) 58.66 (–41.25 to 87.90)
Influenza
positived









































































































































































TABLE 10 Overall vaccine effectiveness for laboratory-confirmed influenza for various influenza types and subtypes in people aged 65–74 years in Scotland (2010–16)








Vaccine effectiveness (95% CI)












Influenza Ac 6/8 75.00 41/62 66.13 11.43 23.75 (–1005.13 to 94.74) –130.96 (–6164.46 to 91.48)
A(H1N1) 3/4 75.00 44/66 66.67 5.71 –34.53 (–10,492.47 to 98.29) 100.00 (–3.43E+53 to 100.00)
A(H3) 2/2 100.00 45/68 66.18 2.86 –8.41E+27 (–inf to 100.00) –7.33E+172 (–inf to 100.00)
Influenza B 2/2 100.00 45/68 66.18 2.86 100.00 (–inf to 100.00) 100.00 (–inf to 100.00)
Influenza
positived




Influenza Ac 34/44 77.27 201/298 67.45 12.87 –51.60 (–271.90 to 38.20) –46.06 (–264.66 to 41.50)
A(H1N1) 12/15 80.00 223/327 68.20 4.39 –66.92 (–619.06 to 61.25) –51.30 (–579.46 to 66.31)
A(H3) 16/19 84.21 219/323 67.80 5.56 –253.35 (–1593.54 to 26.27) –669.38 (–7677.05 to 23.89)
Influenza B 10/14 71.43 225/328 68.60 4.09 34.55 (–180.26 to 84.71) 45.60 (–152.01 to 88.26)
Influenza
positived
44/58 75.86 191/284 67.25 16.96 –25.43 (–175.38 to 42.87) –17.04 (–161.96 to 47.70)
Diabetes
mellitus
Influenza Ac 38/52 73.08 329/429 76.69 10.81 50.02 (–9.24 to 77.13) 49.22 (–11.31 to 76.84)
A(H1N1) 13/19 68.42 354/462 76.62 3.95 58.44 (–30.95 to 86.81) 59.52 (–30.04 to 87.40)
A(H3) 16/18 88.89 351/463 75.81 3.74 –37.95 (–624.27 to 73.72) –43.05 (–651.03 to 72.75)
Influenza B 14/17 82.35 353/464 76.08 3.53 –66.82 (–808.29 to 69.36) –61.40 (–886.95 to 73.61)
Influenza
positived




















Vaccine effectiveness (95% CI)













Influenza Ac 6/8 75.00 135/183 73.77 4.19 67.77 (–221.12 to 96.77) 100.00 (–inf to 100.00)
A(H1N1) 3/3 100.00 138/188 73.40 1.57 92.84 (–inf to 100.00) –1.14E+138 (–inf to 100.00)
A(H3) 1/1 100.00 140/190 73.68 0.52 –8E+11 (–inf to 100.00) –2.14E+19 (–inf to 100.00)
Influenza B 8/10 80.00 133/181 73.48 5.24 43.45 (–856.17 to 96.66) 34.58 (–1089.97 to 96.40)
Influenza
positived
14/18 77.78 127/173 73.41 9.42 59.57 (–136.58 to 93.09) 61.62 (–148.18 to 94.07)
Chronic kidney
disease
Influenza Ac 31/45 68.89 241/320 75.31 12.33 56.98 (5.23 to 80.47) 60.15 (11.32 to 82.09)
A(H1N1) 11/18 61.11 261/347 75.22 4.93 67.19 (–14.61 to 90.61) 71.44 (–3.93 to 92.15)
A(H3) 10/14 71.43 262/351 74.64 3.84 62.85 (–62.04 to 91.48) 71.24 (–37.04 to 93.96)
Influenza B 10/14 71.43 262/351 74.64 3.84 40.63 (–163.49 to 86.62) 77.23 (–135.16 to 97.79)
Influenza
positived
41/58 70.69 231/307 75.24 15.89 55.71 (10.27 to 78.14) 59.90 (17.23 to 80.57)
eBMI > 25 kg/m2 Influenza Ac 25/28 89.29 190/239 79.50 10.49 2.39 (–272.14 to 74.39) –16.90 (–352.53 to 69.80)
A(H1N1) 19/21 90.48 196/246 79.67 7.87 –17.06 (–465.56 to 75.77) –25.32 (–526.88 to 74.95)
A(H3) 1/1 100.00 214/266 80.45 0.37 –3.2E+12 (–inf to 100.00) 100.00 (–inf to 100.00)
Influenza B 9/10 90.00 206/257 80.16 3.75 19.89 (–616.34 to 91.04) 32.04 (–238.13 to 68.98)
Influenza
positived
34/38 89.47 181/229 79.04 14.23 6.45 (–204.17 to 71.23) –2.42 (–238.13 to 68.98)
–inf, infinity.
a Adjusted for time (days) only.
b Adjusted for time (days), season, age and swab location (i.e. hospital or GP).
c Influenza A subtyped + unsubtyped.
d Influenza A+ B.








































































































































































TABLE 11 Overall vaccine effectiveness for laboratory-confirmed influenza for various influenza types and subtypes in people aged 75–84 years in Scotland (2010–16)








Vaccine effectiveness (95% CI)













Influenza Ac 65/111 58.56 522/855 61.05 11.49 23.20 (–19.47 to 50.63) 22.63 (–20.86 to 50.48)
A(H1N1) 22/29 75.86 565/937 60.30 3.00 –88.16 (–391.61 to 27.98) –91.64 (–413.21 to 28.44)
A(H3) 29/59 49.15 558/907 61.52 6.11 53.55 (14.37 to 74.81) 52.02 (11.10 to 74.10)
Influenza B 9/18 50.00 578/948 60.97 1.86 50.96 (–44.37 to 83.34) 47.97 (–56.81 to 82.74)
Influenza
positived
74/127 58.27 513/839 61.14 13.15 30.83 (–4.20 to 54.09) 29.84 (–6.20 to 53.65)
Chronic heart
disease
Influenza Ac 94/116 81.03 502/693 72.44 14.34 –4.52 (–8186 to 39.93) –6.93 (–87.95 to 39.17)
A(H1N1) 21/22 95.45 575/787 73.06 2.72 –520.47 (–4722.90 to 20.18) –855.25 (–10,783.76 to 16.16)
A(H3) 50/63 79.37 546/746 73.19 7.79 17.73 (–17.85 to 62.37) 17.25 (–79.69 to 61.89)
Influenza B 13/15 86.67 583/794 73.43 1.85 –13.32 (–453.61 to 76.80) –17.24 (–547.17 to 78.76)
Influenza
positived
105/129 81.40 491/680 72.21 15.95 –7.43 (–81.86 to 36.54) –6.91 (–82.98 to 37.54)
Asthma Influenza Ac 47/54 87.04 289/392 73.72 12.11 –2.36 (–160.98 to 59.85) 5.13 (–144.10 to 63.13)
A(H1N1) 16/17 94.12 320/429 74.59 3.81 –589.17 (–6684.50 to 29.99) –462.54 (–5311.69 to 41.52)
A(H3) 23/27 85.19 313/419 74.70 6.05 59.46 (–102.83 to 91.90) 57.84 (–123.12 to 92.03)
Influenza B 12/17 70.59 324/429 75.52 3.81 82.90 (31.45 to 95.73) 85.67 (32.32 to 96.97)
Influenza
positived




















Vaccine effectiveness (95% CI)












Influenza Ac 1/3 33.33 21/33 63.64 8.33 –7.33E+172 (–inf to 100.00) –7.33E+172 (–inf to 100.00)
A(H1N1) 0/0 NA 22/36 61.11 0.00 –7.33E+172 (–inf to 100.00) –7.33E+172 (–inf to 100.00)
A(H3) 1/2 50.00 21/34 61.76 5.56 –7.33E+172 (–inf to 100.00) –7.33E+172 (–inf to 100.00)
Influenza B 0/0 NA 22/36 61.11 0.00 –7.33E+172 (–inf to 100.00) –7.33E+172 (–inf to 100.00)
Influenza
positived




Influenza Ac 52/69 75.36 305/411 74.21 14.38 40.38 (–20.90 to 70.60) 41.42 (–20.88 to 1.61)
A(H1N1) 6/9 66.67 351/471 74.52 1.88 13.08 (–396.56 to 84.78) –16.11 (–640.71 to 81.80)
A(H3) 36/44 81.82 321/436 73.62 9.17 24.42 (–96.62 to 70.95) 28.39 (–90.33 to 73.06)
Influenza B 4/6 66.67 353/474 74.47 1.25 69.59 (–161.12 to 96.46) 80.46 (–108.59 to 98.17)
Influenza
positived
55/74 74.32 302/406 74.38 15.42 43.71 (–9.06 to 70.95) 45.80 (–6.61 to 72.44)
Diabetes
mellitus
Influenza Ac 47/59 79.66 361/470 76.81 11.15 38.36 (–34.39 to 71.73) 41.72 (–33.00 to 74.46)
A(H1N1) 7/10 70.00 401/519 77.26 1.89 64.10 (–73.55 to 92.57) 71.98 (–147.90 to 96.83)
A(H3) 27/33 81.82 381/496 76.81 6.24 28.57 (–114.68 to 76.24) 20.23 (–155.69 to 75.11)
Influenza B 14/15 93.33 394/514 76.65 2.84 –153.11 (2005.78 to 69.58) –157.16 (–2141.99 to 70.50)
Influenza
positived




Influenza Ac 5/6 83.33 64/94 68.09 6.00 100.00 (–inf to 100.00) 100.00 (–inf to 100.00)
A(H1N1) 2/2 100.00 67/98 68.37 2.00 –7.7E+14 (–inf to 100.00) –2.20E+57 (–inf to 100.00)
A(H3) 2/2 100.00 67/98 68.37 2.00 –2.3E+18 (–inf to 100.00) 100.00 (–inf to 100.00)
Influenza B 1/1 100.00 68/99 68.69 1.00 –3.84E+60 (–inf to 100.00) –4.8E+15 (–inf to 100.00)









































































































































































TABLE 11 Overall vaccine effectiveness for laboratory-confirmed influenza for various influenza types and subtypes in people aged 75–84 years in Scotland (2010–16)








Vaccine effectiveness (95% CI)












Influenza Ac 65/79 82.28 418/559 74.78 12.38 –3.69 (–107.95 to 48.30) –2.72 (–110.53 to 49.89)
A(H1N1) 14/17 82.35 469/621 75.52 2.66 26.69 (–259.64 to 85.060) 32.97 (–272.50 to 97.94)
A(H3) 33/39 84.62 450/599 75.13 6.11 –30.70 (–257.36 to 52.20) –28.59 (–264.90 to 54.68)
Influenza B 14/15 93.33 469/623 75.28 2.35 –133.50 (–1849.28 to 72.03) –138.54 (–2232.41 to 75.60)
Influenza
positived
78/93 83.87 405/545 74.31 14.58 –12.78 (–117.03 to 41.40) –8.23 (–115.20 to 45.57)
eBMI > 25 kg/m2 Influenza Ac 15/18 83.33 153/192 79.69 8.57 49.07 (–106.34 to 87.43) 68.17 (–60.99 to 93.71)
A(H1N1) 12/13 84.62 157/197 79.70 6.19 40.82 (–204.51 to 88.50) 67.98 (–110.77 to 95.14)
A(H3) 0/0 NA 168/210 80.00 0.00 1.36E–11 (–inf to 100.00) 2.21E–12 (–inf to 100.00)
Influenza B 4/5 80.00 164/205 80.00 2.38 5.86 (–921.74 to 91.33) –1024.20 (–46,864.21 to 73.09)
Influenza
positived
19/23 82.61 149/187 79.68 10.95 39.90 (–103.98 to 82.29) 57.17 (–58.87 to 88.45)
–inf, infinity; NA, not applicable.
a Adjusted for time (days) only.
b Adjusted for time (days), season, age and swab location (i.e. hospital or GP).
c Influenza A subtyped + unsubtyped.
d Influenza A+ B.






















Vaccine effectivenessa (95% CI)












Influenza Ac 249/450 55.33 1708/3274 52.17 12.08 15.43 (–5.18 to 32.00) 15.42 (–5.55 to 32.23)
A(H1N1) 96/170 56.47 1861/3554 52.36 4.56 10.27 (–26.39 to 36.30) 8.44 (–30.05 to 35.54)
A(H3) 101/184 54.89 1856/3540 52.43 4.94 15.05 (–18.61 to 39.16) 15.25 (–18.75 to 39.52)
Influenza B 47/92 51.09 1910/3632 52.59 2.47 37.90 (3.53 to 60.03) 36.34 (0.68 to 59.19)
Influenza positived 296/540 54.81 1661/3184 52.17 14.50 20.45 (2.88 to 34.84) 19.78 (1.77 to 34.49)
Chronic heart disease Influenza Ac 198/289 68.51 1318/2063 63.89 12.29 22.44 (–4.18 to 42.26) 30.75 (5.81 to 49.08)
A(H1N1) 61/97 62.89 1455/2255 64.52 4.12 34.99 (–4.40 to 59.52) 35.94 (–5.35 to 61.05)
A(H3) 85/119 71.43 1431/2233 64.08 5.06 12.11 (–38.70 to 44.30) 27.83 (–15.90 to 55.06)
Influenza B 43/59 72.88 1473/2293 64.24 2.51 20.07 (–48.62 to 57.01) 13.63 (–65.01 to 54.79)
Influenza positived 237/344 68.90 1279/2008 63.70 14.63 20.26 (–4.54 to 39.17) 26.79 (2.76 to 44.88)
Asthma Influenza Ac 223/534 41.76 1669/3622 46.08 12.85 41.37 (28.06 to 52.21) 48.62 (35.56 to 59.03)
A(H1N1) 89/232 38.36 1803/3924 45.95 5.58 41.73 (20.86 to 57.10) 48.42 (27.19 to 63.45)
A(H3) 88/188 46.81 1804/3968 45.46 4.52 34.23 (8.81 to 52.57) 36.69 (9.68 to 55.63)
Influenza B 53/167 31.74 1839/3989 46.10 4.02 66.51 (52.07 to 76.60) 65.46 (49.30 to 76.47)









































































































































































TABLE 12 Overall vaccine effectiveness for laboratory-confirmed influenza for various influenza types and subtypes in people aged ≥ 85 years in Scotland (2010–16) in various








Vaccine effectivenessa (95% CI)










Chronic liver disease Influenza Ac 17/39 43.59 154/312 49.36 11.11 50.22 (–9.54 to 77.38) 54.37 (–6.38 to 80.43)
A(H1N1) 6/14 42.86 165/337 48.96 3.99 62.62 (–49.99 to 90.68) 59.06 (–72.08 to 90.26)
A(H3) 5/17 47.06 163/334 48.80 4.84 60.93 (–131.78 to 93.41) 54.38 (–158.14 to 91.94)
Influenza B 5/9 55.56 166/342 48.54 2.56 –10.94 (–504.25 to 79.63) –3.23 (–681.43 to 86.36)
Influenza positived 22/47 46.81 149/304 49.01 13.39 43.28 (–15.18 to 72.07) 48.89 (–7.70 to 75.74)
Chronic neurological
disease
Influenza Ac 120/165 72.73 688/1065 64.60 13.41 4.49 (–42.98 to 36.21) 7.23 (–40.00 to 38.52)
A(H1N1) 31/45 68.89 777/1185 65.57 3.66 14.78 (–74.67 to 58.42) 9.53 (–88.14 to 56.50)
A(H3) 64/80 80.00 744/1150 64.70 6.50 –46.06 (–172.98 to 21.84) –31.40 (–152.54 to 31.63)
Influenza B 18/28 64.29 790/1202 65.72 2.28 56.39 (–4.76 to 81.85) 54.69 (–12.49 to 81.75)
Influenza positived 137/192 71.35 671/1038 64.64 15.61 13.67 (–25.79 to 40.74) 15.42 (–24.37 to 42.47)
Diabetes mellitus Influenza Ac 156/232 67.24 1119/1643 68.11 12.37 35.42 (9.87 to 53.73) 34.82 (8.00 to 53.82)
A(H1N1) 49/78 62.82 1226/1797 68.22 4.16 37.49 (–7.04 to 63.49) 34.04 (–15.49 to 62.33)
A(H3) 71/96 73.96 1204/1779 67.68 5.12 2.54 (–67.55 to 43.31) 1.85 (–72.18 to 4.05)
Influenza B 41/57 71.93 1234/1818 67.88 3.04 29.19 (–37.35 to 63.50) 23.64 (–52.19 to 61.69)




















Vaccine effectivenessa (95% CI)












Influenza Ac 35/57 61.40 392/734 53.41 7.21 52.67 (7.98 to 75.66) 49.52 (–4.19 to 75.54)
A(H1N1) 10/15 66.67 417/776 53.74 1.90 54.69 (–106.62 to 90.06) 43.43 (–21.36 to 89.72)
A(H3) 17/24 70.83 410/767 53.46 3.03 7.56 (–147.54 to 65.48) –26.33 (–257.22 to 55.33)
Influenza B 18/31 58.06 409/760 53.82 3.92 70.04 (25.45 to 87.96) 46.72 (–20.33 to 76.40)
Influenza positived 53/88 60.23 374/703 53.20 11.13 48.60 (14.52 to 69.09) 41.87 (2.56 to 65.33)
Chronic kidney disease
(stage 3–5)
Influenza Ac 134/188 71.28 903/1278 70.66 12.82 32.97 (1.01 to 54.62) 33.14 (–0.54 to 55.54)
A(H1N1) 35/56 62.50 1002/1410 71.06 3.82 60.06 (23.62 to 79.11) 56.31 (14.17 to 77.76)
A(H3) 64/85 75.29 973/1381 70.46 5.80 12.83 (–58.12 to 51.94) 3.43 (–82.66 to 48.94)
Influenza B 33/40 82.50 1004/1426 70.41 2.73 –40.33 (–283.72 to 48.68) –44.59 (–299.58 to 47.69)
Influenza positived 166/225 73.78 871/1241 70.19 15.35 27.94 (49.89 to 15.35) 27.50 (–6.01 to 50.41)
eBMI > 25 kg/m2 Influenza Ac 4/5 80.00 80/101 79.21 4.72 81.77 (–257.22 to 99.07) 100.00 (–inf to 100.00)
A(H1N1) 3/4 75.00 81/102 79.41 3.77 84.24 (–141.32 to 98.97) 100.00 (–inf to 100.00)
A(H3) 0/0 NA 84/106 79.25 0.00 1.07E–11 (–inf to 100.00) –3.60E–12 (–inf to 100.00)
Influenza B 2/2 100.00 82/104 78.85 1.89 –4.8E+16 (–inf to 100.00) 98.52 (–inf to 100.00)
Influenza positived 5/6 83.33 79/100 79.00 5.66 68.78 (–513.65 to 98.41) 100.00 (–2.31E+77 to 100.00)
–inf, infinity; NA, not applicable.
a Adjusted for time (days) only.
b Adjusted for time (days), season, age and swab location (i.e. hospital or GP).
c Influenza A subtyped + unsubtyped.
d Influenza A+ B.








































































































































































TABLE 13 Overall vaccine effectiveness for laboratory-confirmed influenza for various influenza types and subtypes in people aged ≥ 18 years in Scotland (2010–16), for swabs









Vaccine effectiveness (95% CI)










GP Sentinel Influenza Ac 71/399 17.79 647/3302 19.59 10.78 29.33 (5.47 to 47.16) 17.62 (–17.24 to 42.12)
A(H1N1) 17/181 9.39 701/3520 19.91 4.89 71.96 (51.03 to 83.94) 61.13 (27.45 to 79.17)
A(H3) 52/203 25.62 666/3498 19.04 5.49 –26.25 (–77.00 to 9.94) –28.19 (–93.94 to 15.27)
Influenza B 30/220 13.64 688/3481 19.76 5.94 54.39 (29.04 to 70.68) 31.13 (–16.05 to 59.13)
Influenza
positived
98/601 16.31 620/3100 20.00 16.24 36.29 (18.57 to 50.16) 19.14 (–8.80 to 39.91)
GP non-
Sentinel
Influenza Ac 29/104 27.88 73/270 27.04 27.81 36.66 (–31.02 to 69.38) 70.59 (19.97 to 89.19)
A(H1N1) 3/23 13.04 99/351 28.21 6.15 69.22 (–7.88 to 91.22) 74.75 (–14.91 to 94.45)
A(H3) 3/5 60.00 99/369 26.83 1.34 –418.03 (–3560.82 to 26.70) 6.05 (–1302.25 to 93.70)
Influenza B 11/41 26.83 91/333 27.33 10.96 74.67 (0.77 to 93.53) 77.86 (–12.78 to 95.65)
Influenza
positived
37/140 26.43 65/234 27.78 37.43 43.28 (–7.17 to 69.99) 64.01 (16.87 to 84.42)
Hospital Influenza Ac 776/2247 34.53 5819/15,439 37.69 12.70 26.21 (18.38 to 33.28) 27.02 (18.13 to 34.94)
A(H1N1) 259/995 26.03 6336/16,691 37.96 5.63 49.62 (41.54 to 56.58) 34.73 (22.83 to 44.80)
A(H3) 349/773 45.15 6246/16,913 36.93 4.37 –14.31 (–32.59 to 1.46) 18.42 (3.31 to 31.18)
Influenza B 174/551 31.58 6421/17,135 37.47 3.12 41.47 (29.17 to 51.63) 35.04 (19.05 to 47.88)
Influenza
positived
948/2789 33.99 5647/14,897 37.91 15.77 29.90 (23.24 to 35.99) 29.51 (21.78 to 36.47)
a Adjusted for time (days) only.
b Adjusted for time (days), age and number of risk groups.
c Influenza A subtyped + unsubtyped.




















Vaccine effectiveness (95% CI)










18–54 Coronavirus 17/124 13.71 294/2624 11.20 4.51 –30.42 (–123.90 to 24.03) –26.55 (–118.06 to 26.56)
Mycoplasma
pneumoniae
9/70 12.86 305/2699 11.30 2.53 –47.74 (–207.99 to 29.13) –58.04 (–231.04 to 24.55)
Parainfluenza
type 1
3/25 12.00 310/2743 11.30 0.90 –57.56 (–450.79 to 54.93) –54.60 (–441.17 to 55.84)
Parainfluenza
type 2
4/22 18.18 310/2747 11.29 0.79 0.00 (–inf to 100.00) 0.00 (–inf to 100.00)
Rhinovirus 40/337 11.87 274/2431 11.27 12.17 –25.91 (–82.33 to 13.05) –33.88 (–94.46 to 7.84)
Respiratory syncytial
virus
9/101 8.91 305/2667 11.44 3.65 18.90 (–64.31 to 59.97) 23.60 (–55.35 to 62.43)
55–64 Coronavirus 13/37 35.14 142/641 22.15 5.46 –74.31 (–264.18 to 16.57) –64.15 (–246.37 to 22.20)
Mycoplasma
pneumoniae
3/14 21.43 153/668 22.90 2.05 –44.85 (–467.39 to 63.02) –22.00 (–409.71 to 70.80)
Parainfluenza
type 1
0/9 0.00 156/673 23.18 1.32 100.00 (–inf to 100.00) 100.00 (–inf to 100.00)
Parainfluenza
type 2
1/6 16.67 155/676 22.93 0.88 0.00 (–inf to 100.00) 0.00 (–inf to 100.00)
Rhinovirus 14/67 20.90 142/614 23.13 9.84 –35.57 (–165.50 to 30.78) –39.63 (–175.51 to 29.23)
Respiratory syncytial
virus
















































































































































































Vaccine effectiveness (95% CI)










65–74 Coronavirus 25/38 65.79 367/661 55.52 5.44 8.57 (–97.00 to 57.57) 11.27 (–92.39 to 59.08)
Mycoplasma
pneumoniae
5/11 45.45 390/693 56.28 1.56 10.54 (–254.85 to 77.45) 13.31 (–250.11 to 78.53)
Parainfluenza
type 1
4/12 33.33 391/692 56.50 1.70 46.80 (–111.93 to 86.64) 49.03 (–106.45 to 87.42)
Parainfluenza
type 2
4/09 44.44 391/695 56.26 1.28 0.00 (–inf to 100.00) 0.00 (–inf to 100.00)
Rhinovirus 43/83 51.81 353/622 56.75 11.77 –9.12 (–85.25 to 35.72) –9.67 (–86.66 to 35.57)
Respiratory syncytial
virus
30/42 71.43 366/662 55.29 5.97 –82.47 (–283.43 to 13.17) –81.98 (–282.79 to 13.48)
–inf, infinity.
a Adjusted for time (days) only.













TABLE 15 Clinical primary care and hospitalisation outcomes for people aged ≥ 65 years
Outcome Season Vaccine effectiveness (95% CI)
GP consultations
ARI 2015/16 –47.64 (–49.61 to –45.69)
2014/15 –59.28 (–61.47 to –57.12)
2013/14 –55.40 (–57.64 to –53.19)
2012/13 –53.34 (–55.51 to –51.21)
2011/12 –59.69 (–61.99 to –57.42)
2010/11 –46.72 (–49.05 to –44.43)
Influenza or pneumonia 2015/16 –33.66 (–39.61 to –27.97)
2014/15 –34.90 (–40.49 to –29.54)
2013/14 –64.02 (–72.41 to –56.05)
2012/13 –28.70 (–34.41 to –23.22)
2011/12 –58.01 (–65.39 to –50.95)
2010/11 –46.43 (–52.98 to –40.16)
Emergency hospitalisations
Influenza or pneumococcal disease 2015/16 17.28 (15.55 to 18.98)
2014/15 23.40 (21.81 to 24.95)
2013/14 22.41 (20.51 to 24.27)
2012/13 27.56 (25.89 to 29.19)
2011/12 20.58 (18.69 to 22.44)
2010/11 21.19 (19.19 to 23.15)
Deaths 2015/16 31.82 (30.78 to 32.84)
2014/15 38.57 (37.64 to 39.49)
2013/14 34.57 (33.50 to 35.62)
2012/13 33.93 (32.90 to 34.93)
2011/12 34.19 (33.14 to 35.22)
2010/11 39.78 (38.83 to 40.71)
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patient-seasons Relative risk 95% CI
GP
Influenza or pneumonia consultation 2015/16 Unvaccinated 5.20 1.00 NA
Vaccinated 5.85 1.13 1.11 to 1.15
2014/15 Unvaccinated 5.61 1.00 NA
Vaccinated 5.99 1.07 1.05 to 1.09
2013/14 Unvaccinated 4.12 1.00 NA
Vaccinated 4.50 1.09 1.07 to 1.12
2012/13 Unvaccinated 4.79 1.00 NA
Vaccinated 4.98 1.04 1.02 to 1.06
2011/12 Unvaccinated 4.48 1.00 NA
Vaccinated 4.86 1.08 1.06 to 1.11
2010/11 Unvaccinated 3.95 1.00 NA
Vaccinated 4.38 1.11 1.08 to 1.13
ARI consultation 2015/16 Unvaccinated 10.92 1.00 NA
Vaccinated 22.80 2.09 2.06 to 2.11
2014/15 Unvaccinated 10.85 1.00 NA
Vaccinated 23.85 2.20 2.17 to 2.22
2013/14 Unvaccinated 10.57 1.00 NA
Vaccinated 22.58 2.14 2.11 to 2.16
2012/13 Unvaccinated 11.57 1.00 NA
Vaccinated 22.98 1.99 1.96 to 2.01
2011/12 Unvaccinated 10.73 1.00 NA
Vaccinated 22.23 2.07 2.05 to 2.10
2010/11 Unvaccinated 9.67 1.00 NA
Vaccinated 16.91 1.75 1.73 to 1.77
Emergency hospitalisations
Influenza or pneumococcal disease 2015/16 Unvaccinated 1.05 1.00 NA
Vaccinated 1.82 1.73 1.66 to 1.79
2014/15 Unvaccinated 1.27 1.00 NA
Vaccinated 2.22 1.76 1.70 to 1.82
2013/14 Unvaccinated 0.86 1.00 NA
Vaccinated 1.70 1.98 1.90 to 2.07
2012/13 Unvaccinated 1.12 1.00 NA
Vaccinated 1.97 1.75 1.68 to 1.82
2011/12 Unvaccinated 1.00 1.00 NA
Vaccinated 2.15 2.15 2.06 to 2.23
2010/11 Unvaccinated 1.19 1.00 NA
Vaccinated 2.13 1.79 1.73 to 1.85
RESULTS
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TABLE 16 Non-specific clinical primary care and hospitalisation outcome rates and relative risk for people aged





patient-seasons Relative risk 95% CI
Deaths 2015/16 Unvaccinated 11.02 1.00 NA
Vaccinated 9.60 0.87 0.86 to 0.88
2014/15 Unvaccinated 11.80 1.00 NA
Vaccinated 9.78 0.83 0.82 to 0.84
2013/14 Unvaccinated 10.60 1.00 NA
Vaccinated 8.98 0.85 0.84 to 0.86
2012/13 Unvaccinated 11.95 1.00 NA
Vaccinated 10.11 0.85 0.83 to 0.86
2011/12 Unvaccinated 11.59 1.00 NA
Vaccinated 9.55 0.82 0.81 to 0.84
2010/11 Unvaccinated 10.39 1.00 NA
Vaccinated 9.71 0.93 0.92 to 0.95
NA, not applicable.
TABLE 17 Influenza and pneumonia emergency hospitalisation and vaccine effectiveness for those aged < 65 years









2010/11 Pre 1 September 2010 11 October 2010 27.77 (10.80 to 41.51)
2010/11 Mid 12 December 2010 13 March 2011 22.40 (10.19 to 32.95)
2010/11 Post 14 March 2011 30 June 2012 15.73 (2.83 to 26.92)
2011/12 Pre 1 September 2011 19 February 2012 25.97 (16.43 to 34.43)
2011/12 Mid 20 February 2012 6 May 2012 12.84 (–2.01 to 25.54)
2011/12 Post 7 May 2012 30 June 2012 21.28 (4.39 to 35.19)
2012/13 Pre 1 September 2012 9 December 2012 26.40 (9.87 to 39.89)
2012/13 Mid 10 December 2012 21 April 2013 29.17 (20.97 to 36.53)
2012/13 Post 22 April 2013 30 June 2013 4.43 (–14.04 to 19.91)
2013/14 Pre 1 September 2013 2 February 2014 22.71 (11.71 to 32.34)
2013/14 Mid 3 February 2014 13 April 2014 9.47 (–7.19 to 23.53)
2013/14 Post 14 April 2014 30 June 2014 24.07 (11.02 to 35.20)
2014/15 Pre 1 September 2014 14 December 2014 22.71 (7.92 to 35.12)
2014/15 Mid 15 December 2014 19 April 2015 23.52 (15.48 to 30.80)
2014/15 Post 20 April 2015 30 June 2015 18.01 (4.61 to 29.53)
2015/16 Pre 1 September 2015 27 December 2015 11.24 (–3.12 to 23.60)
2015/16 Mid 28 December 2015 15 May 2016 21.14 (12.88 to 28.61)
2015/16 Post 16 May 2016 30 June 2016 18.05 (0.77 to 32.33)
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TABLE 18 Vaccine uptake in Scotland (2010–16) for people aged ≥ 65 years in each CHP
CHP
Vaccine uptake by season (%)
2010/11 2011/12 2012/13 2013/14 2014/15 2015/16
S03000001 78.80 77.30 78.30 79.30 80.54 78.11
S03000002 78.35 79.58 80.89 75.28 75.78 76.16
S03000003 78.40 76.98 78.52 73.53 77.14 78.20
S03000004 64.46 67.46 63.64 63.41 62.95 61.53
S03000005 100.00 100.00 NA NA NA NA
S03000006 70.40 61.30 64.94 78.54 77.77 74.89
S03000007 62.49 63.39 63.24 63.61 62.85 61.15
S03000008 55.23 54.74 55.71 56.24 54.75 53.22
S03000009 80.15 80.96 81.00 81.02 80.14 77.10
S03000010 73.25 74.65 74.94 75.78 74.53 73.68
S03000011 77.15 78.12 79.29 79.51 78.88 78.14
S03000013 0.00 0.00 0.00 0.00 50.00 66.67
S03000014 40.00 37.50 33.33 37.50 33.33 20.00
S03000015 76.85 78.67 80.80 79.19 79.54 78.05
S03000017 61.97 63.22 63.77 63.19 61.81 62.60
S03000018 75.04 76.07 81.05 77.22 75.97 74.48
S03000020 77.82 77.25 82.39 79.31 81.06 80.27
S03000023 74.68 76.09 76.91 80.08 79.39 75.83
S03000025 19.47 20.50 19.72 20.24 19.78 19.95
S03000029 65.85 66.77 66.50 73.10 72.63 67.24
S03000030 78.80 79.05 81.38 81.54 79.16 79.40
S03000031 46.85 47.47 47.66 47.25 46.30 44.74
S03000032 56.06 56.65 58.13 57.90 57.29 56.01
S03000035 49.20 50.03 51.11 51.34 50.82 49.99
S03000036 0.00 0.00 0.00 NA NA NA
S03000037 76.79 76.67 81.07 78.16 79.32 78.62
S03000038 76.76 76.04 78.10 78.51 77.98 75.19
S03000039 72.21 76.20 76.81 77.54 76.19 76.48
S03000040 73.69 72.60 72.84 75.05 73.79 73.85
S03000041 0.00 0.00 0.00 0.00 NA 100.00
S03000042 57.80 58.75 58.78 58.76 57.94 57.07
S03000043 61.27 61.94 63.53 64.43 63.36 61.82
S03000044 62.66 63.21 63.62 63.41 62.94 60.74
NA, not applicable.
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Modelling an unmeasured confounder
Estimates from published data were used to model the effect of inadequately measured confounders on
vaccine effectiveness in the cohorts for emergency hospitalisations due to pneumonia or influenza. The
baseline vaccine effectiveness is that derived from pooling the estimates for the six seasons in Table 12.
The pooled estimate, using a random-effects meta-analysis, is 22.9% (95% CI 19.8% to 25.8%).
It was found that a scenario of 15% prevalence for unaccounted frail individuals in the unvaccinated
population, with frailty causing a fourfold increase in the risk of emergency hospitalisation and with a
5% presence of frailty among the vaccinated population, resulted in the vaccine no longer being effective
(vaccine effectiveness 2.75, 95% CI –1.11 to 6.49).9 A twofold increase in risk of hospitalisation would
have relatively little impact, although it does reduce the magnitude of the vaccine effect estimate. By
varying the prevalence of frailty and its risk on outcome, the change in vaccine effectiveness estimates for
a number of scenarios (Table 19) were modelled.27 The study also found that this model can be displayed
effectively in graphical form (Figures 3 and 4). In Figures 4 and 5, the vaccine effectiveness is estimated
given levels of the unmeasured confounder in the vaccinated population (x-axis) and unvaccinated
population (each of the lines representing a different prevalence of the unmeasured confounder in the
vaccinated population). At points where the prevalence of the unmeasured confounder is the same in the
unvaccinated individuals and vaccinated individuals, then the baseline result is achieved, as there is no
difference in the level of the unmeasured variable in the two groups.
Vaccine safety
The LAIV was found to be safe in children, with no adverse reactions found (Figures 5 and 6). The number
of adverse events recorded for children was very small and the CIs are wide. In most cases, fewer adverse
events were reported among children who were vaccinated than in those who were unvaccinated,
suggesting that relatively healthy children are the ones who received the LAIV.
The TIV was found to be safe, with no association with adverse events (Figures 7 and 8). The exception to this
finding was a statistically significant increase in allergic reaction (non-anaphylaxis) coded in the GP database;
here, the TIV incidence RR (without the interaction term) was 1.33 (96% CI 1.13 to 1.56; p < 0.001). The
Benjamini–Hochberg-adjusted p-value for this interaction test was 0.009 for GP consultations. This is the
only adverse event for which there was a suggestion that the TIV was associated with a temporary increase
in consultations following vaccination. In a majority of potential adverse events, those people who were
vaccinated were at lower risk of GP consultation post vaccination than those people who were unvaccinated.
TABLE 19 Sensitivity analysis to quantify the effects of a hypothetical unmeasured confounder on the cohort
analysis results
Increase in the risk of outcome on
account of the confounder
Prevalence of confounder (%)
Emergency hospitalisation for
pneumonia or influenza, adjusted





– 0 0 22.88 (19.81 to 25.84)
Doubled 5 0 19.03 (15.80 to 22.13)
Doubled 10 5 19.21 (15.99 to 22.31)
Doubled 215 5 15.54 (12.17 to 18.77)
Quadrupled 5 0 11.31 (7.78 to 14.71)
Quadrupled 10 5 12.82 (–9.35 to 16.16)
Quadrupled 15 5 2.75 (–1.11 to 6.49)
DOI: 10.3310/hta24670 HEALTH TECHNOLOGY ASSESSMENT 2020 VOL. 24 NO. 67
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Simpson et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
49
0.0 0.2 0.4 0.6 0.8 1.0



























FIGURE 3 Unmeasured residual confounding and vaccine effectiveness (doubling of risk in emergency
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FIGURE 4 Unmeasured residual confounding and vaccine effectiveness (quadrupling of risk in emergency
hospitalisations for influenza and pneumonia).
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FIGURE 5 General practice consultations: adverse events in children with LAIV interactions. Note that dots to the
left of the vertical dashed line at 1 correspond to adverse events where the RR comparing the risk period with
the pre- or post-risk period is lower among those children vaccinated than in those children unvaccinated. Dots to
the right of the vertical dashed line at 1, and where all of the horizontal line corresponding to the 95% CI is above 1,
indicate adverse events where there is a potential association with receipt of the vaccine. Some of the estimates are
based on very small numbers and the right-hand side of the plot is truncated at 10.
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FIGURE 6 Hospitalisation: adverse events in children with LAIV interactions.
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FIGURE 7 General practice consultations: adverse events in adults with TIV interactions.
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FIGURE 8 Hospitalisation: adverse events in adults with TIV interactions.
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Chapter 5 Discussion
In the first year of full rollout of LAIV to all preschool-aged and primary school-aged children in 2014/15[an influenza season with circulating influenza A(H3N2)], vaccine effectiveness was positive (but non-
significant) against RT-PCR laboratory-confirmed influenza. Highly significant vaccine effectiveness was
found for season 2015/16, in which influenza A(H1N1) predominated. The LAIV was found to be safe
among children, with no increased adverse reactions.
For those people considered at risk and who were aged < 65 years, TIV conferred significant protection against
influenza for four of the six seasons. The two seasons in which no statistically significant vaccine effectiveness
could be demonstrated coincided with seasons in which there was low levels of circulating influenza virus.
Positive significant vaccine effectiveness was found among those people aged ≥ 65 years for one season
(2013/14), a less severe season in which one predominate strain [influenza A(H1N1)] circulated. TIV was
found to be safe overall. The finding of increased GP consultation for (non-anaphylaxis) allergic reaction
may be related to common TIV issues at the injection site (e.g. arm soreness and redness).10
The acceptability of the LAIV programme among children registered with our practices was evidenced by
high initial and then increasing uptake in both preschool- and primary school-aged children. There were
also high levels of uptake of the TIV among those people aged ≥ 65 years, all of whom were able to receive
the vaccine for free as part of the programme. High levels of TIV uptake was found for adults with at-risk
diseases and who were aged 55–64 years. Uptake of the vaccine varied among different groups. Vaccine
effectiveness, measured using hospital and GP non-specific clinical outcomes, was assessed using the
Simonsen et al.40 framework and was found to suffer from bias. The chosen instrumental variable, vaccine
uptake by geographically determined health area, was determined not to be valid.
The LAIV uptake among 2- to 4-year-olds in the SIVE II practices in the 2014/15 season (39.3%) was
similar to uptake in England and Wales (38.7%).51 The modest uptake that was found among at-risk
patients (particularly those aged between 18 and 55 years) has been found previously in our SIVE study
and in other data sets (e.g. QResearch and questionnaire surveys).52,53 The uptake in this study for older
adults was lower than that found using GP routine reporting in Scotland [e.g. 59.2–67.1% vs. 74.5%
(for those aged ≥ 65 years) in 2015–16].54
When comparing different groups of patients stratified by age band, there was greater power in this study
than in the SIVE study to determine if uptake differed among groups of patients.47 This study found, for
example, that children in the least deprived quintile were more likely to receive influenza vaccine than those
in the most deprived quintile; a similar pattern was found in uptake across deprivation groups using England
and Wales GP data.51 As in the SIVE study, it was also found that older people who had an emergency
admission were less likely to be vaccinated;47 however, this may be an example of the healthy vaccine effect
bias in which less sick older people are more likely to be vaccinated.40
The findings of positive vaccine effectiveness (against RT-PCR-confirmed influenza) for LAIV in the two
seasons for which there was full vaccination rollout to primary school-aged and preschool-aged children
(significantly positive in 2015/16) have been found elsewhere. For example, this study’s 2015/16 results
confirm those of a UK study (which included Scottish GPs) [overall vaccine effectiveness 58.1% vs. 57.6%;
influenza B 88.3% vs. 81.4%; and influenza A(H1N1) 40.4% vs. 41.5%, respectively].55 However, the
study’s results were in contrast to those from the US Centers for Disease Control and Prevention, which
found that no protection was conveyed to children vaccinated with LAIV in 2014/15 (21% vs. −3%) and in
2015/16 (58% vs. 3%).56,57
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Trivalent influenza vaccine effectiveness among adults was the lowest when the predominant circulating
subtype of influenza was H3N2 and highest when the predominant circulating subtype of influenza was
H1N1. This was found for the pre-2009/10 seasons in the SIVE study.47 Low vaccine effectiveness for H3N2
has been found elsewhere.58 Reasons for poor vaccine effectiveness for H3N2 seasons have been postulated.
Chicken eggs are used for culturing clinical isolates and for large-scale production of vaccines. However,
influenza virus can mutate while being grown in chicken eggs, which could have an influence on antigenicity
and lead to decreasing vaccine effectiveness.59 Others have suggested that low H3N2 vaccine effectiveness in
adults may not be due to egg adaptation, but rather caused by low vaccine immunogenicity in a subset of the
population.60 The finding of reduced TIV effectiveness in those people aged ≥ 65 years reinforces the evidence
base on which the Joint Committee on Vaccination and Immunisation has made a recommendation of the
preferential use of an adjuvanted seasonal influenza vaccine for the 2018/19 season.61
When compared with vaccine effectiveness in other vaccines administered to children and adults, influenza
vaccine effectiveness was found to be lower. For example, rotavirus vaccination among young children was
90% effective in children aged > 12 months;62 vaccination for measles, mumps, rubella and varicella was
85% effective against varicella;63 and herpes zoster vaccine was 69% effective in adults aged ≥ 60 years.64
In contrast to Wong et al.,42 who determined that geographical zones could be used as an instrumental
variable, this study’s use of the geographical area – CHP – did not result in a strong instrumental variable.43
The well-known safety profile of the TIV has been confirmed in this study using a novel observational study
design to reduce bias.9,10,46 However, there is less evidence regarding the safety of LAIV in children.8 Previously
reported short-term adverse effects of LAIV from clinical trials include bronchospasm, headache, nausea,
vomiting and diarrhoea. Serious adverse events include pneumonia, bronchopneumonia, bronchiolitis and
bronchitis. This study found no increase in adverse harms (mild and serious) from the LAIV used.
Study limitations
The estimates of vaccine uptake (particularly for those people aged ≥ 65 years) are lower relative to those
reported by HPS, which are based on vaccine claim counts by all GPs in Scotland. SIVE II study practices
may have been located in areas with a low level of vaccine uptake (e.g. more deprived areas). However, in
this study it was not possible to check this as the study did not have practice identifiers. In similar, previous
studies with smaller numbers of practices,30,47,65,66 but using similar data sets, vaccine uptake among those
people aged ≥ 65 years was closer to national estimates of 75%. If SIVE II practices have actual lower
levels of vaccine uptake, then this study’s estimates of vaccine effectiveness will be unbiased. If this study
has missing data on vaccination, then the effect of the misclassification of some vaccinated individuals as
unvaccinated will have moved the estimates of vaccine effectiveness towards zero, and so the vaccine
effectiveness reported in this study may be too low. However, the estimates of vaccine effectiveness are
unlikely to be substantially lower, as the pooled estimates for the TND for any influenza among those
people aged ≥ 65 years over the six seasons is 17.9% (95% CI 5.2% to 28.7%), whereas from the cohort
for emergency hospitalisation for pneumonia or influenza the vaccine effectiveness is 22.9% (95% CI
19.8% to 25.8%). Therefore, there was little scope for big increases in the estimated vaccine effectiveness,
assuming that all of the misclassified unvaccinated individuals did not experience an event. The study was
unable to calculate whether or not there was any indirect effect of the LAIV. The indirect impact of LAIV,
defined as reduction in cumulative disease incidence over the same period between pilot and non-pilot
areas in non-target age groups (< 4 years of age and > 11 years of age), was measured in England;
however, no statistically significant indirect protection to other age groups was found.67 The work of
other groups exploring this issue will continue to be monitored. Owing to the observational nature of
this study, which uses routinely collected data, residual confounding may be present or unaccounted for.
A no-cost extension to this project was granted: this was due to the complexity of extracting and linking
data from a number of disparate data sets (challenging in terms of putting the necessary governance
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permissions in place and technical processes required for data extraction and linkage). Future projects
requiring data linkage should build adequate time to address governance and technical challenges.
The study recruited 230 practices, which was fewer than the 500 practices (of a total of 998 Scottish GPs)
originally stated in the grant application. Substantial resource was committed to the process of recruitment
(e.g. presentation to GP national users groups, GP newsletter advertisements, e-mail and telephone
recruitment, and several reminders). Despite the lower than expected final number of GPs participating in
this project, to date this is one of the largest individual patient-level primary care recruitment and data
extractions to take place in Scotland (with one-fifth of practices participating). Only a small number of
practices responded to turn down the offer to participate (almost all with no explanation). With the
introduction of national strategies to use primary care data for research purposes [e.g. the Scottish Primary
Care Information Resource; URL: www.spire.scot (accessed 1 October 2018)], it is hoped that ambitious
recruitment targets, such as in this study, will be seen as more feasible.
Recommendations for further research
The monitoring of the LAIV programme with enhanced Sentinel swabbing of preschool- and primary
school-aged children should continue. Future studies should be planned to further monitor the seasonal
influenza vaccine in at-risk patients and such studies will continue to require expertise in data linkage
and advanced analyses of these complex data sets. Replication of vaccine effectiveness and safety in LAIV
and TIV in other countries (that have these influenza vaccine programmes) is also needed to confirm this
study’s results. A future study will be required to monitor the safety and effectiveness of the adjuvanted
TIV available to older people for the 2018/19 season.61 Any future evaluation work should contain a health
economics analysis to help understand at what level of vaccine effectiveness it becomes cost-effective to
recommend vaccination or continue to vaccinate.
Conclusions
Using these data, it was found that LAIV was safe and effective in decreasing RT-PCR-confirmed influenza
in children. TIV was safe and significantly effective (in most seasons) for those people aged 18–64 years
with positive vaccine effectiveness and in most seasons for those people aged ≥ 65 years (although this
was statistically significant in only one season). Higher vaccine effectiveness was found among younger
adults with asthma. Few countries’ health systems allow for the integrated and accessible data recording
that made this study possible and which made it feasible to centrally collate almost all hospitalisations
and deaths attributed to influenza, allowing for completeness of reporting. LAIV was found to be safe,
with vaccine effectiveness comparable to that found for TIV. TIV immunisation for at-risk adults in primary
health-care settings is effective.
DOI: 10.3310/hta24670 HEALTH TECHNOLOGY ASSESSMENT 2020 VOL. 24 NO. 67
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Simpson et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science




The authors would like to thank staff at Albasoft Ltd, HPS, the WoSSVC, the Asthma UK Centre forApplied Research and the ISD electronic Data Research and Innovation Service team, and would also like
to thank the GPs contributing data to the study and members of the Independent Steering Committee and
Asthma UK Centre for Applied Research patient and public involvement team for overseeing this work.
Contributions of authors
Colin R Simpson (Professor of Population Health) was the principal investigator and led the writing of
this report.
Nazir I Lone (Senior Clinical Fellow, Intensive Care) helped design the study, draft and write the project
protocol and revise the report for important intellectual content.
Kim Kavanagh (Senior Lecturer) helped design the study, draft and write the project protocol and revise
the report for important intellectual content.
Tanya Englishby (Research Fellow) carried out the analyses and helped to design the study and write
the report.
Chris Robertson (Professor of Statistics) carried out the analyses and helped to design the study and write
the report.
Jim McMenamin (Consultant Epidemiologist) helped design the study, draft and write the project
protocol and revise the report for important intellectual content.
Beatrix von Wissman (Specialist Trainee in Public Health) helped design the study, draft and write the
project protocol and revise the report for important intellectual content.
Eleftheria Vasileiou (PhD student) helped design the study, draft and write the project protocol and
revise the report for important intellectual content.
Christopher C Butler (Professor of Primary Care) helped design the study, draft and write the project
protocol and revise the report for important intellectual content.
Lewis D Ritchie (Professor of Primary Care) helped design the study, draft and write the project protocol
and revise the report for important intellectual content.
Rory Gunson (Consultant Clinical Scientist) helped design the study, draft and write the project protocol
and revise the report for important intellectual content.
Jürgen Schwarze (Edward Clark Chair of Child Life and Health) helped design the study, draft and write
the project protocol and revise the report for important intellectual content.
Aziz Sheikh (Professor of Primary Care Research and Development) helped design the study, draft and
write the project protocol and revise the report for important intellectual content.
DOI: 10.3310/hta24670 HEALTH TECHNOLOGY ASSESSMENT 2020 VOL. 24 NO. 67
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Simpson et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
59
Publications
Simpson CR, Lone NI, Kavanagh K, Robertson C, McMenamin J, von Wissman B, et al. Evaluating the
effectiveness, impact and safety of live attenuated and seasonal inactivated influenza vaccination: protocol
for the Seasonal Influenza Vaccination Effectiveness II (SIVE II) study. BMJ Open 2017;7:e014200.
Vasileiou E, Sheikh A, Butler CC, Robertson C, Kavanagh K, Englishby T, et al. Seasonal influenza vaccine
effectiveness in people with asthma: a national test-negative design case-control study. Clin Infect Dis
2020;71:e94–e104.
Data-sharing statement
All data requests should be submitted to the corresponding author for consideration. Access to
anonymised data may be granted following review.
Patient data
This work uses data provided by patients and collected by the NHS as part of their care and support. Using
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